var title_f15_61_16336="Nocardia on Gram stain";
var content_f15_61_16336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain of Nocardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nocardia appear as delicate, filamentous, branching gram-positive rods that are indistinguishable from Actinomyces.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley W Chapman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16336=[""].join("\n");
var outline_f15_61_16336=null;
var title_f15_61_16337="C5 compression fracture";
var content_f15_61_16337=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    C5 compression fracture lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 14 year old male sustained a comminuted C5 compression fracture with 25 percent loss of anterior vertebral body height relative to the posterior portion (black arrow) after a head on collision with hyperflexion while playing football.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alison Chantal Caviness, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16337=[""].join("\n");
var outline_f15_61_16337=null;
var title_f15_61_16338="Suction irrigator";
var content_f15_61_16338=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Suction irrigator for laparoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This combination suction and irrigating device is used for laparoscopic surgery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16338=[""].join("\n");
var outline_f15_61_16338=null;
var title_f15_61_16339="Enanthem in Coxsackie infection";
var content_f15_61_16339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Enanthem in coxsackievirus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scattered petechiae appear centrally, and there is a vesicle posteriorly at the junction of the hard and soft palates. Coxsackievirus produces lesions toward the posterior of the oropharynx, whereas herpes simplex virus appears anteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16339=[""].join("\n");
var outline_f15_61_16339=null;
var title_f15_61_16340="Contents: General pediatrics";
var content_f15_61_16340=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       General pediatrics",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			General pediatrics",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Calculators",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13697\">",
"           Calculator: Apgar score",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9463\">",
"           Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9751\">",
"           Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/14/36070\">",
"           Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/60/35782\">",
"           Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/49/43796\">",
"           Calculator: Body mass index for boys (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/19/12596\">",
"           Calculator: Body mass index for girls (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/47/22262\">",
"           Calculator: CDC height for age percentiles for boys (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/7/22646\">",
"           Calculator: CDC height for age percentiles for girls (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/50/35619\">",
"           Calculator: CDC weight for height percentiles for boys (77 to 121 cm tall)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/37/2644\">",
"           Calculator: CDC weight for height percentiles for girls (77 to 121 cm tall)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/25/16788\">",
"           Calculator: CDC/NCHS infant head circumference for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/34/34339\">",
"           Calculator: CDC/NCHS infant length for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/10/162\">",
"           Calculator: CDC/NCHS infant weight for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/53/6997\">",
"           Calculator: CDC/NCHS infant weight for length percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/40/24193\">",
"           Calculator: Glomerular filtration rate estimate by Schwartz formula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/60/8129\">",
"           Calculator: Maintenance fluid calculation for children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30769\">",
"           Calculator: Mid-parental target height prediction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/63/5109\">",
"           Calculator: Newborn hyperbilirubinemia assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9860\">",
"           Calculator: PELD score for end-stage liver disease (patients less than 12 years old)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36485\">",
"           Calculator: WHO Assessment of Malnutrition in Boys 0 to 2 Years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/32/30213\">",
"           Calculator: WHO Assessment of Malnutrition in Boys 2 to 5 years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/1/36885\">",
"           Calculator: WHO Assessment of Malnutrition in Girls 0 to 2 Years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/48/30469\">",
"           Calculator: WHO Assessment of Malnutrition in Girls 2 to 5 years Old",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27241\">",
"           Approach to chest pain in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Care of the hospitalized child",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33798\">",
"           Auxiliary services in pediatrics",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Child abuse and neglect",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/5/35927\">",
"           Child abuse: Social and medicolegal issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/62/18408\">",
"           Child neglect and emotional abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/23/31097\">",
"           Childhood exposure to intimate partner violence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/27/23990\">",
"           Differential diagnosis of suspected child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/23/11641\">",
"           Differential diagnosis of the orthopedic manifestations of child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35258\">",
"           Evaluation of sexual abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/15/11510\">",
"           Management and sequelae of sexual abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/16/36104\">",
"           Munchausen syndrome by proxy (medical child abuse)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/19/24890\">",
"           Physical abuse in children: Diagnostic evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/54/26473\">",
"           Physical abuse in children: Epidemiology and clinical manifestations",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Child care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/20/8520\">",
"           Adoption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/5/27737\">",
"           Children with special health care needs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/13/16602\">",
"           Comprehensive health care for children in foster care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/15/43255\">",
"           Developmental and behavioral implications for military children with deployed parents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/58/32679\">",
"           Support services for the care of chronically ill children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ear; nose; oropharynx; and larynx",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/35/8760\">",
"           Acute otitis media in children: Diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/60/29642\">",
"           Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/0/21514\">",
"           Acute otitis media in children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/28/41417\">",
"           Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12823\">",
"           Cerumen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/36/35397\">",
"           Ear barotrauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6615\">",
"           Jaw fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22153\">",
"           Otitis media with effusion (serous otitis media) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/61/43992\">",
"           Retropharyngeal infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/37/27224\">",
"           Symptomatic relief of sore throat in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Environmental influences",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/23/31097\">",
"           Childhood exposure to intimate partner violence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/24/394\">",
"           Childhood lead poisoning: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/47/11001\">",
"           Childhood lead poisoning: Exposure and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/5/21594\">",
"           Childhood lead poisoning: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/27/16823\">",
"           Information and educational resources for occupational and environmental health issues in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/51/13114\">",
"           Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/13/14553\">",
"           Overview of occupational and environmental health",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/36/14921\">",
"           Prevention of firearm injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/25/40343\">",
"           Television and media violence",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastroenterology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/20/11593\">",
"           Causes of acute abdominal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/63/15354\">",
"           Constipation in children: Etiology and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/9/44182\">",
"           Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/17/1306\">",
"           Evaluation of the child and adolescent with chronic abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/52/6984\">",
"           Management of the child and adolescent with chronic abdominal pain",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genetic diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/15/26874\">",
"           Clinical features and diagnosis of Down syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/58/13224\">",
"           Management of Down syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Growth and development",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/54/3946\">",
"           Etiology and evaluation of macrocephaly in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/51/36665\">",
"           Etiology and evaluation of microcephaly in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/40/42633\">",
"           Normal growth patterns in infants and prepubertal children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/25/1434\">",
"           Normal puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/18/38185\">",
"           School readiness",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gynecologic issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/6/25703\">",
"           Clinical features and diagnosis of candidemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/11/12473\">",
"           Diagnosis and management of congenital anomalies of the vagina",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/19/43316\">",
"           Gynecologic examination of the newborn and child",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/47/31481\">",
"           Overview of Candida infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/29/26072\">",
"           Vulvovaginal complaints in the prepubertal child",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hearing",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12823\">",
"           Cerumen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/36/35397\">",
"           Ear barotrauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/38/19050\">",
"           Etiology of hearing impairment in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/19/44344\">",
"           Evaluation of hearing impairment in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/13/27865\">",
"           Screening the newborn for hearing loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/14/29927\">",
"           Treatment of hearing impairment in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Immunization",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/5/43097\">",
"           Allergic reactions to vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/36/21066\">",
"           Autism and chronic disease: Little evidence for thimerosal as a contributing factor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/14/26857\">",
"           Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/10/13480\">",
"           Clinical trials of human papillomavirus vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/27/34233\">",
"           Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/37/5722\">",
"           Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/37/601\">",
"           Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/32/23050\">",
"           Meningococcal vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/14/7402\">",
"           Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/52/17223\">",
"           Poliovirus vaccination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/31/42489\">",
"           Prevention of Haemophilus influenzae infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/26/37289\">",
"           Prevention of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/17/19738\">",
"           Recommendations for the use of human papillomavirus vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/62/40937\">",
"           Rotavirus vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/18/27946\">",
"           Seasonal influenza vaccination in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/61/19418\">",
"           Standard childhood vaccines: Parental hesitancy or refusal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/56/39818\">",
"           Standard immunizations for children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/39/26229\">",
"           The life cycle, natural history, and immunology of human papillomaviruses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/36/23110\">",
"           Treatment of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/7/40057\">",
"           Vaccinia virus as the smallpox vaccine",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infectious diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/30/9706\">",
"           Approach to the child with fever of unknown origin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33128\">",
"           Approach to the child with peripheral lymphadenopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/44/16074\">",
"           Bronchiolitis in infants and children: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/19/27962\">",
"           Bronchiolitis in infants and children: Treatment; outcome; and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30744\">",
"           Causes of peripheral lymphadenopathy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/49/24346\">",
"           Clinical features and diagnosis of seasonal influenza in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33480\">",
"           Clinical features of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/54/22377\">",
"           Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24857\">",
"           Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/48/22278\">",
"           Epidemiology of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/63/38905\">",
"           Etiologies of fever of unknown origin in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8632\">",
"           Etiology and clinical manifestations of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/26/37289\">",
"           Prevention of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/1/31767\">",
"           Treatment and prevention of parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/36/23110\">",
"           Treatment of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Injury prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/31/11767\">",
"           Overview of pediatric injury prevention: Epidemiology; history; application",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40617\">",
"           Peer violence and violence prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/58/13225\">",
"           Prevention of bicycle injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/52/12106\">",
"           Prevention of falls in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/36/14921\">",
"           Prevention of firearm injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/3/37944\">",
"           Prevention of poisoning in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intoxications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/57/2970\">",
"           Acute iron poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/62/15337\">",
"           Button and cylindrical battery ingestion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/24/394\">",
"           Childhood lead poisoning: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/47/11001\">",
"           Childhood lead poisoning: Exposure and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/5/21594\">",
"           Childhood lead poisoning: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/12/7367\">",
"           Classification of trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/10/29865\">",
"           Clinical manifestations and evaluation of potentially toxic plant ingestions in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/1/37913\">",
"           Decontamination of poisoned children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/2/16426\">",
"           Food poisoning in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/27/16823\">",
"           Information and educational resources for occupational and environmental health issues in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/51/13114\">",
"           Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/60/43974\">",
"           Management of ibuprofen poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/21/22874\">",
"           Opioid intoxication in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nephrology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30584\">",
"           Evaluation of microscopic hematuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26262\">",
"           Evaluation of proteinuria in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/62/11237\">",
"           Anencephaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/8/35977\">",
"           Approach to the child with headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29209\">",
"           Clinical features of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/50/41768\">",
"           Epidemiology and etiology of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/54/5994\">",
"           Hydrocephalus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/10/26793\">",
"           Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/8/5257\">",
"           Intellectual disability (mental retardation) in children: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/59/40887\">",
"           Intellectual disability (mental retardation) in children: Management; outcomes; and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/37/15962\">",
"           Management and prognosis of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/3/18490\">",
"           Management of migraine headache in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/38/12906\">",
"           Minor head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/28/13770\">",
"           Overview of developmental coordination disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/62/33767\">",
"           Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/57/3991\">",
"           Primary (congenital) encephalocele",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/39/42616\">",
"           Breastfeeding: Parental education and support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/0/18441\">",
"           Dietary recommendations for toddlers, preschool, and school-age children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/12/14538\">",
"           Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42967\">",
"           Fast food for children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34631\">",
"           Food protein-induced proctitis/colitis and enteropathy of infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/43/10938\">",
"           Introducing solid foods and vitamin and mineral supplementation during infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/60/18378\">",
"           Management of childhood obesity in the primary care setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/16/30985\">",
"           Management of failure to thrive (undernutrition) in children younger than two years",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/36/6727\">",
"           Nutritional composition of human milk for full-term infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/9/9369\">",
"           Organic foods and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/21/38233\">",
"           Poor weight gain in children older than two years of age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/4/8266\">",
"           Vegetarian diets for children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ophthalmology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/32/10762\">",
"           Retinopathy of prematurity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Oral health",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/42/39590\">",
"           Anatomy and development of the teeth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/55/19320\">",
"           Oral habits and orofacial development in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/26/33192\">",
"           Preventive dental care and counseling for infants and young children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26340\">",
"           Reduction of temporomandibular joint (TMJ) dislocation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/32/30216\">",
"           Soft tissue lesions of the oral cavity in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Orthopedics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/26/8616\">",
"           Acquired torticollis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/4/42057\">",
"           Approach to the child with a limp",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/55/27511\">",
"           Approach to the child with bow-legs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/3/6199\">",
"           Approach to the child with knock-knees",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/45/19162\">",
"           Back pain in children and adolescents: Overview of causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/30/27113\">",
"           Clinical features and diagnosis of developmental dysplasia of the hip",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/23/11641\">",
"           Differential diagnosis of the orthopedic manifestations of child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2679\">",
"           Evaluation of the child with back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/6/12392\">",
"           Osgood-Schlatter disease (tibial tuberosity avulsion)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/21/16729\">",
"           Overview of hip pain in childhood",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/9/23706\">",
"           Overview of the causes of limp in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24581\">",
"           Patellar dislocations in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38532\">",
"           Radial head subluxation (nursemaid's elbow)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/42/23209\">",
"           Slipped capital femoral epiphysis (SCFE)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/54/15208\">",
"           Splinting of musculoskeletal injuries",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/34/31272\">",
"           Apparent life-threatening event in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/18/1322\">",
"           Clinical manifestations and diagnosis of hemophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24857\">",
"           Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8632\">",
"           Etiology and clinical manifestations of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/7/32889\">",
"           Evaluation of cervical spine injuries in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/44/35529\">",
"           Overview of complementary and alternative medicine in pediatrics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/20/37194\">",
"           Sudden infant death syndrome: Risk factors and risk reduction strategies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/0/36872\">",
"           Sudden unexpected infant death including SIDS: Initial management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/60/5066\">",
"           What's new in pediatrics",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Physical examination",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/19/43316\">",
"           Gynecologic examination of the newborn and child",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/30/34280\">",
"           The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/36/38471\">",
"           The pediatric physical examination: Chest and abdomen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/30/19943\">",
"           The pediatric physical examination: General principles and standard measurements",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/59/11194\">",
"           The pediatric physical examination: HEENT",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/3/10295\">",
"           The pediatric physical examination: The perineum",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Primary care practice",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/35/20024\">",
"           Clinical practice guidelines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/22/14694\">",
"           Evidence-based medicine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/8/39047\">",
"           Preparing an office practice for pediatric emergencies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psychiatric disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/18/26922\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/61/32730\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/19/14650\">",
"           Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27241\">",
"           Approach to chest pain in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/30/37354\">",
"           Chronic asthma in children younger than 12 years: Controller medications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15319\">",
"           Chronic asthma in children younger than 12 years: Definition, epidemiology, and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/25/26010\">",
"           Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39670\">",
"           Chronic asthma in children younger than 12 years: Quick-relief agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/29/44505\">",
"           Etiology and management of hoarseness in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Screening",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/2/2088\">",
"           Newborn screening",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/13/43225\">",
"           Screening tests in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/13/27865\">",
"           Screening the newborn for hearing loss",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Speech and language",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/26/30114\">",
"           Case illustrating the evaluation of speech and language impairment in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/22/10599\">",
"           Emergent literacy including language development",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/29/44505\">",
"           Etiology and management of hoarseness in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/57/21399\">",
"           Etiology of speech and language disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26343\">",
"           Evaluation and treatment of speech and language disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/0/4102\">",
"           Evaluation of the child with hoarseness",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43766\">",
"           Causes of painless scrotal swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/39/32376\">",
"           Causes of scrotal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/21/40281\">",
"           Etiology and evaluation of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/38/2663\">",
"           Evaluation of scrotal pain or swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/0/7178\">",
"           Management of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/46/41705\">",
"           Neonatal circumcision: Risks and benefits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/9/7315\">",
"           Patient information: Bedwetting in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/57/15256\">",
"           Techniques for neonatal circumcision",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/44/17098\">",
"           Undescended testes (cryptorchidism) in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Viral infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/49/24346\">",
"           Clinical features and diagnosis of seasonal influenza in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33480\">",
"           Clinical features of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/54/22377\">",
"           Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24857\">",
"           Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/58/15272\">",
"           Epidemiology of influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/48/22278\">",
"           Epidemiology of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8632\">",
"           Etiology and clinical manifestations of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/29/40408\">",
"           Parvovirus B19 infection during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/26/37289\">",
"           Prevention of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/56/7050\">",
"           Respiratory syncytial virus infection: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/17/15640\">",
"           Respiratory syncytial virus infection: Prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/27/38327\">",
"           Respiratory syncytial virus infection: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/18/27946\">",
"           Seasonal influenza vaccination in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/1/31767\">",
"           Treatment and prevention of parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/36/23110\">",
"           Treatment of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-AC61C9CAE9-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f15_61_16340=[""].join("\n");
var outline_f15_61_16340=null;
var title_f15_61_16341="Tinzaparin: Patient drug information";
var content_f15_61_16341=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tinzaparin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"     see \"Tinzaparin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F228098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Innohep&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       People who have had recent spinal anesthesia, epidurals, or spinal taps are more likely to have bleeding problems when started on this drug. This bleeding rarely happens, but can be very bad. Tell your doctor if you have had any spinal care. Do not take any other blood-thinner drugs including nonsteroidal anti-inflammatory drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705929",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor you use this drug before you get spinal anesthesia or a spinal treatment.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691756",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat blood clots.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin the blood so that clots will not form.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703037",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tinzaparin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to pork products, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703685",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Low platelet count due to heparin or bad bleeding problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697216",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have eye problems from high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stroke, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697238",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had any recent surgery or dental care, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697167",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an ulcer in the stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care to stop injury and avoid falls or crashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fall or crash when you hit your head. Talk with your doctor even if you feel fine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695995",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin on the right or left side of the belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site where you give the shot with each shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11096 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16341=[""].join("\n");
var outline_f15_61_16341=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228098\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028777\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028779\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028778\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028783\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028784\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028786\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028781\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028782\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028787\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028788\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=related_link\">",
"      Tinzaparin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_61_16342="Velamentous cord insertion";
var content_f15_61_16342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Velamentous cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The umbilical cord placental insertion site is membranous. The velamentous vessels are surrounded only by fetal membranes, with no Wharton's jelly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eduardo Zambrano, MD, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16342=[""].join("\n");
var outline_f15_61_16342=null;
var title_f15_61_16343="Butalbital and acetaminophen: Drug information";
var content_f15_61_16343=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Butalbital and acetaminophen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/26/3493?source=see_link\">",
"    see \"Butalbital and acetaminophen: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13135418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3276743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bupap;",
"     </li>",
"     <li>",
"      Cephadyn [DSC];",
"     </li>",
"     <li>",
"      Orviban&reg; CF;",
"     </li>",
"     <li>",
"      Phrenilin&reg; Forte;",
"     </li>",
"     <li>",
"      Promacet;",
"     </li>",
"     <li>",
"      Sedapap&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3276747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Miscellaneous;",
"     </li>",
"     <li>",
"      Barbiturate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3276782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Tension or muscle contraction headache:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Butalbital 50 mg and acetaminophen 300-325 mg: 1-2 tablets every 4 hours as needed (maximum: 6 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Butalbital 50 mg and acetaminophen 650 mg: One tablet/capsule every 4 hours as needed (maximum: 6 doses/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F14197853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Tension or muscle contraction headache:",
"     </b>",
"     Children &ge;12 years: Oral: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3276783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing. Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3276784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, use with caution; dose reduction or alternate therapy should be considered, especially with severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3276785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, use with caution; dose reduction or alternate therapy should be considered, especially with severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3276787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Butalbital 50 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bupap, Cephadyn [DSC], Promacet, Sedapap&reg;: Butalbital 50 mg and acetaminophen 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orbivan&reg; CF: Butalbital 50 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phrenilin&reg; Forte: Butalbital 50 mg and acetaminophen 650 mg [may contain benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3276745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3276748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of the symptomatic complex of tension or muscle contraction headache",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5118633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3276759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequently observed:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, lightheadedness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Intoxicated feeling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infrequently observed:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, confusion, depression, euphoria, excitement, faintness, fever, headache, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hyperhidrosis, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot spells",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, dysphagia, heartburn, flatulence, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Leg pain, muscle fatigue, numbness, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Heavy eyelids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Earache, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Diuresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, high energy, shaky feeling, sluggishness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Limited to important or life-threatening: Toxic epidermal necrolysis, erythema multiforme",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3276754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to butalbital, acetaminophen, or any component of the formulation; porphyria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3276755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Acetaminophen may cause severe hepatotoxicity, potentially requiring liver transplant or resulting in death; hepatotoxicity is usually associated with excessive acetaminophen intake (&gt;4 g/day).",
"     </b>",
"     Risk is increased with alcohol use, pre-existing liver disease, and intake of more than one source of acetaminophen-containing medications. Chronic daily dosing in adults has also resulted in liver damage in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported with acetaminophen use; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage limit: Limit acetaminophen dose from all sources (prescription and OTC) to &lt;4 g/day.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F3276766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3276765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Barbiturates may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Barbiturates may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Barbiturates may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Barbiturates may increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Barbiturates may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Barbiturates may decrease the serum concentration of Etoposide Phosphate. Barbiturates may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: Barbiturates may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Barbiturates.  Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Barbiturates may enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Barbiturates may enhance the CNS depressant effect of Meperidine. Barbiturates may increase serum concentrations of the active metabolite(s) of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Barbiturates may enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Barbiturates may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Barbiturates may enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Barbiturates may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3276768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3276749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3276750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Withdrawal seizures were reported in an infant 2 days after birth following maternal use of a butalbital product during the last 2 months of pregnancy; butalbital was detected in the newborns serum. Also refer to acetaminophen monograph for information specific to acetaminophen.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3276752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3276753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Barbiturates and acetaminophen are excreted in breast milk. Also refer to acetaminophen monograph for information specific to acetaminophen.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4588985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Phrenilin Forte Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-650 mg (100): $927.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bupap Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-650 mg (100): $240.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Butalbital-Acetaminophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-325 mg (100): $37.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Orbivan CF Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-300 mg (100): $240.00",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3276773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Butalbital is a short- to intermediate-acting barbiturate. Barbiturates depress the sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, hypnosis, and dose-dependent respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acetaminophen inhibits the synthesis of prostaglandins in the central nervous system and peripherally blocks pain impulse generation; produces antipyresis from inhibition of hypothalamic heat-regulating center.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3276775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see Acetaminophen monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Butalbital: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Butalbital: 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Butalbital: 35 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Butalbital: Urine (59% to 88% as unchanged drug or metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16343/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16343/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16343/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16343/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16343/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16343/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16343/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, &ldquo;Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),&rdquo;",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, &ldquo;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16343/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9017 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-213.134.24.46-B0B7A2AA67-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16343=[""].join("\n");
var outline_f15_61_16343=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13135418\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276743\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276747\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276782\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14197853\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276783\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276784\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276785\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276787\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276745\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276748\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5118633\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276759\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276754\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276755\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276766\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276765\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276768\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276749\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276750\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276752\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276753\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4588985\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276773\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276775\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9017\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9017|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/26/3493?source=related_link\">",
"      Butalbital and acetaminophen: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_61_16344="Albuterol (salbutamol): Drug information";
var content_f15_61_16344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Albuterol (salbutamol): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/50/40741?source=see_link\">",
"    see \"Albuterol (salbutamol): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"    see \"Albuterol (salbutamol): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AccuNeb&reg;;",
"     </li>",
"     <li>",
"      ProAir&reg; HFA;",
"     </li>",
"     <li>",
"      Proventil&reg; HFA;",
"     </li>",
"     <li>",
"      Ventolin&reg; HFA;",
"     </li>",
"     <li>",
"      VoSpire ER&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F130977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Airomir&trade;;",
"     </li>",
"     <li>",
"      Apo-Salvent&reg;;",
"     </li>",
"     <li>",
"      Apo-Salvent&reg; AEM;",
"     </li>",
"     <li>",
"      Apo-Salvent&reg; CFC Free;",
"     </li>",
"     <li>",
"      Apo-Salvent&reg; Sterules;",
"     </li>",
"     <li>",
"      Dom-Salbutamol;",
"     </li>",
"     <li>",
"      Mylan-Salbutamol Respirator Solution;",
"     </li>",
"     <li>",
"      Mylan-Salbutamol Sterinebs P.F.;",
"     </li>",
"     <li>",
"      Novo-Salbutamol HFA;",
"     </li>",
"     <li>",
"      Nu-Salbutamol;",
"     </li>",
"     <li>",
"      PHL-Salbutamol;",
"     </li>",
"     <li>",
"      PMS-Salbutamol;",
"     </li>",
"     <li>",
"      ratio-Ipra-Sal;",
"     </li>",
"     <li>",
"      ratio-Salbutamol;",
"     </li>",
"     <li>",
"      Sandoz-Salbutamol;",
"     </li>",
"     <li>",
"      Teva-Salbutamol;",
"     </li>",
"     <li>",
"      Teva-Salbutamol Sterinebs P.F.;",
"     </li>",
"     <li>",
"      Ventolin&reg;;",
"     </li>",
"     <li>",
"      Ventolin&reg; Diskus;",
"     </li>",
"     <li>",
"      Ventolin&reg; HFA;",
"     </li>",
"     <li>",
"      Ventolin&reg; I.V. Infusion;",
"     </li>",
"     <li>",
"      Ventolin&reg; Nebules P.F.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F131027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta",
"      <sub>",
"       2",
"      </sub>",
"      Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F130981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bronchospasm:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Metered-dose inhaler (90 mcg/puff):",
"     </i>",
"     2 puffs every 4-6 hours as needed (NIH Guidelines, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Metered-dose inhaler (100 mcg/puff): Airomir&trade; (Canadian availability):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Acute treatment: 1-2 puffs; additional puffs may be necessary if inadequate relief however patients should be advised to promptly consult healthcare provider or seek medical attention if no relief from acute treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Maintenance: 1-2 puffs 3-4 times daily (maximum: 8 puffs daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Solution for nebulization:",
"     </i>",
"     2.5 mg 3-4 times daily as needed; Quick relief: 1.25-5 mg every 4 to 8 hours as needed (NIH Guidelines, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     2-4 mg/dose 3-4 times/day; maximum dose not to exceed 32 mg/day (divided doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release: 8 mg every 12 hours; maximum dose not to exceed 32 mg/day (divided doses). A 4 mg dose every 12 hours may be sufficient in some patients, such as adults of low body weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      I.V. continuous infusion",
"     </i>",
"     (Canadian labeling; product not available in U.S.): Severe bronchospasm and status asthmaticus: Initial: 5 mcg/minute; may increase up to 10-20 mcg/minute at 15- to 30-minute intervals if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Exacerbation of asthma (acute, severe)",
"     </b>",
"     (NIH Guidelines, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Metered-dose inhaler:",
"     </i>",
"     4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Solution for nebulization:",
"     </i>",
"     2.5-5 mg every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours as needed,",
"     <b>",
"      or",
"     </b>",
"     10-15 mg/hour by continuous nebulization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Exercise-induced bronchospasm (prevention):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Metered-dose inhaler (90 mcg/puff):",
"     </i>",
"     2 puffs 5-30 minutes prior to exercise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Metered-dose inhaler (100 mcg/puff): Airomir&trade; (Canadian availability):",
"     </i>",
"     2 puffs 30 minutes prior to exercise",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F131004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"      see \"Albuterol (salbutamol): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bronchospasm:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral, regular release:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 2-6 years: 0.1-0.2 mg/kg/dose 3 times/day (maximum: 12 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 6-12 years: 2 mg/dose 3-4 times/day (maximum: 24 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;12 years: 2-4 mg/dose 3-4 times/day (maximum: 32 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Oral, extended release:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 6-12 years: 4 mg every 12 hours (maximum: 24 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;12 years: 8 mg every 12 hours (maximum: 32 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Metered-dose inhaler (90 mcg/puff):",
"     </i>",
"     NIH Guidelines, 2007: Quick relief:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &le;4 years: 2 puffs every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 5-11 years: 2 puffs every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years: 2 puffs every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Metered-dose inhaler (100 mcg/puff): Airomir&trade; (Canadian availability):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children 6-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Acute treatment: 1 puff; additional puffs may be necessary if inadequate relief however patients should be advised to promptly consult healthcare provider or seek medical attention if no relief from acute treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Maintenance: 1 puff; may increase to maximum of 1 puff 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Solution for nebulization:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 2-12 years (AccuNeb&reg;): 0.63-1.25 mg 3-4 times daily as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;12 years: 2.5 mg 3-4 times daily as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     NIH Guidelines, 2007: Quick relief:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &le;4 years: 0.63-2.5 mg every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;5 years: 1.25-5 mg every 4-8 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Exacerbation of asthma (acute, severe)",
"     </b>",
"     (NIH Guidelines, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Metered-dose inhaler (90 mcg/puff):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &lt;12 years: 4-8 puffs every 20 minutes for 3 doses, then every 1-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &ge;12 years: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Solution for nebulization:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &lt;12 years: 0.15 mg/kg (minimum: 2.5 mg) every 20 minutes for 3 doses, then 0.15-0.3 mg/kg (maximum: 10 mg) every 1-4 hours as needed,",
"     <b>",
"      or",
"     </b>",
"     0.5 mg/kg/hour by continuous nebulization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &ge;12 years: 2.5-5 mg every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours as needed,",
"     <b>",
"      or",
"     </b>",
"     10-15 mg/hour by continuous nebulization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Exercise-induced bronchospasm (prevention):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Metered-dose inhaler (90 mcg/puff):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &le;4 years: 1-2 puffs 5 minutes prior to exercise (NIH Guidelines, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &gt;4 years: 2 puffs 5-30 minutes prior to exercise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Metered-dose inhaler (100 mcg/puff): Airomir&trade; (Canadian availability):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children 6-11 years: 1 puff 30 minutes prior to exercise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F130982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bronchospasm (treatment): Oral: 2 mg 3-4 times/day; maximum: 8 mg 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F130983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment.  No dosage adjustment required (including patients on hemodialysis, peritoneal dialysis, or CRRT; Aronoff, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ProAir&reg; HFA: 90 mcg/inhalation (8.5 g) [chlorofluorocarbon free; 200 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proventil&reg; HFA: 90 mcg/inhalation (6.7 g) [chlorofluorocarbon free; 200 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ventolin&reg; HFA: 90 mcg/inhalation (18 g) [chlorofluorocarbon free; 200 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ventolin&reg; HFA: 90 mcg/inhalation (8 g) [chlorofluorocarbon free; 60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization: 0.083% [2.5 mg/3 mL] (30s, 60s); 0.5% [100 mg/20 mL] (1s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization [preservative free]: 0.021% [0.63 mg/3 mL] (25s); 0.042% [1.25 mg/3 mL] (25s, 30s); 0.083% [2.5 mg/3 mL] (25s, 30s, 60s); 0.5% [2.5 mg/0.5 mL] (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AccuNeb&reg;: 0.021% [0.63 mg/3 mL] (25s); 0.042% [1.25 mg/3 mL] (25s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: 2 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 4 mg, 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VoSpire ER&reg;: 4 mg, 8 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Airomir&trade;: 100 mcg/inhalation (3.7 g) [chlorofluorocarbon free; 100 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Airomir&trade;: 100 mcg/inhalation (6.7 g) [chlorofluorocarbon free; 200 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulphate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ventolin&reg; I.V.: 1 mg/1mL (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes aerosol",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F130955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metered-dose inhaler: Shake well before use; prime prior to first use, and whenever inhaler has not been used for &gt;2 weeks or when it has been dropped, by releasing 3-4 test sprays into the air (away from face). Airomir&trade; Canadian product labeling recommends releasing a minimum of 4 test sprays when priming. HFA inhalers should be cleaned with warm water at least once per week; allow to air dry completely prior to use. A spacer device or valved holding chamber is recommended for use with metered-dose inhalers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution for nebulization: Concentrated solution should be diluted prior to use. Blow-by administration is not recommended, use a mask device if patient unable to hold mouthpiece in mouth for administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion solution (Canadian labeling; product not available in U.S.): Do not inject undiluted. Reduce concentration by at least 50% before infusing. Administer as a continuous infusion via infusion pump.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Do not crush or chew extended release tablets.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F5167761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravenous solution: Stable in water for injection, NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, and D",
"     <sub>",
"      5",
"     </sub>",
"     NS when mixed in PC bags or glass bottles. Avoid addition of other medications to infusion solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution for nebulization:",
"     <b>",
"      Compatible",
"     </b>",
"     with cromolyn sodium, budesonide inhalation suspension, ipratropium solution for nebulization",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F130954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease; prevention of exercise-induced bronchospasm",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Albuterol may be confused with Albutein&reg;, atenolol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Proventil&reg; may be confused with Bentyl&reg;, PriLOSEC&reg;, Prinivil&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Salbutamol may be confused with salmeterol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ventolin&reg; may be confused with phentolamine, Benylin&reg;, Vantin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F131025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Incidence of adverse effects is dependent upon age of patient, dose, and route of administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Angina, atrial fibrillation, arrhythmias, chest discomfort, chest pain, extrasystoles, flushing, hyper-/hypotension, palpitation, supraventricular tachycardia, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: CNS stimulation, dizziness, drowsiness, headache, insomnia, irritability, lightheadedness, migraine, nervousness, nightmares, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypokalemia, lactic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, dry mouth, dyspepsia, gastroenteritis, nausea, unusual taste, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Micturition difficulty",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection: Pain, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps, musculoskeletal pain, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Otitis media, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma exacerbation, bronchospasm, cough, epistaxis, laryngitis,  oropharyngeal drying/irritation, oropharyngeal edema, pharyngitis, rhinitis, upper respiratory inflammation, viral respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylaxis, diaphoresis,  lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anxiety, glossitis, hoarseness, metabolic acidosis, myocardial ischemia, pulmonary edema, throat irritation, tongue ulceration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F130958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to albuterol or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Injection formulation (Canadian labeling; product not available in U.S.): Hypersensitivity to albuterol or any component of the formulation; tachyarrhythmias; risk of abortion during first or second trimester",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F130939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Appropriate use: Optimize anti-inflammatory treatment before initiating maintenance treatment with albuterol. Do not use as a component of chronic therapy without an anti-inflammatory agent. Only the mildest forms of asthma (Step 1 and/or exercise-induced) would not require concurrent use based upon asthma guidelines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia or hypertension or HF); beta-agonists may cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may also increase risk of arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may increase serum glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with glaucoma; may elevate intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may decrease serum potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Face masks should be used in children &lt;4 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use may indicate deterioration of asthma, and treatment must not be delayed. A spacer device or valved holding chamber is recommended when using a metered-dose inhaler.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Blockers: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F130971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Avoid or limit caffeine (may cause CNS stimulation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid ephedra, yohimbe (may cause CNS stimulation). Avoid St John's wort (may decrease the levels/effects of albuterol).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F130961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Albuterol crosses the placenta (Boulton, 1997). Congenital anomalies (cleft palate, limb defects) have rarely been reported following maternal use during pregnancy. Multiple medications were used in most cases, no specific pattern of defects has been reported, and no relationship to albuterol has been established. The amount of albuterol available systemically following inhalation is significantly less in comparison to oral doses.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Albuterol is the preferred short acting beta agonist when treatment for asthma is needed during pregnancy (NAEPP, 2005; NAEPP,  2007).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Albuterol may affect uterine contractility. Maternal pulmonary edema and other adverse events have been reported when albuterol was used for tocolysis. Albuterol is not approved for use as a tocolytic; use caution when needed to treat bronchospasm in pregnant women. Use of the injection (Canadian product; not available in the U.S.) is specifically contraindicated in women during the first or second trimester who may be at risk of threatened abortion.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F130987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16137852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if albuterol is excreted into breast milk. The amount of albuterol available systemically following inhalation is significantly less in comparison to oral doses. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. The use of beta-2-receptor agonists are not considered a contraindication to breast feeding (NAEPP, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F130962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral forms should be taken with water 1 hour before or 2 hours after meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F130960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (ProAir HFA Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     108 (90 Base) mcg/ACT (8.5 g): $53.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Proventil HFA Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     108 (90 Base) mcg/ACT (6.7 g): $62.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Ventolin HFA Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     108 (90 Base) mcg/ACT (8 g): $19.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nebulization",
"     </b>",
"     (AccuNeb Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.63 mg/3 mL (3 mL): $2.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 mg/3 mL (3 mL): $2.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nebulization",
"     </b>",
"     (Albuterol Sulfate Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.63 mg/3 mL (3 mL): $1.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 mg/3 mL (3 mL): $1.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (2.5 MG/3ML) 0.083% (3 mL): $1.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (5 MG/ML) 0.5% (1): $0.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (5 MG/ML) 0.5% (20 mL): $17.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Albuterol Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/5 mL (473 mL): $30.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Albuterol Sulfate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $140.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (100): $262.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (VoSpire ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $232.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (100): $436.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Albuterol Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $587.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $587.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F130949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow, and/or other pulmonary function tests; blood pressure, heart rate; CNS stimulation; serum glucose, serum potassium; asthma symptoms; arterial or capillary blood gases (if patients condition warrants)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F130963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aero-Vent (PH);",
"     </li>",
"     <li>",
"      Aerolin (BR, CN, GR);",
"     </li>",
"     <li>",
"      Aeromol (TH);",
"     </li>",
"     <li>",
"      Airmax (CO);",
"     </li>",
"     <li>",
"      Airomir (AU, CR, FR, GT, HN, LU, NI, NZ, PA, SE, SV, UY);",
"     </li>",
"     <li>",
"      Asmacaire (PH);",
"     </li>",
"     <li>",
"      Asmadil (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Asmalin Pulmoneb (PH);",
"     </li>",
"     <li>",
"      Asmatol (AR);",
"     </li>",
"     <li>",
"      Asmidon (JP);",
"     </li>",
"     <li>",
"      Asmol (SG);",
"     </li>",
"     <li>",
"      Asmol CFC-Free (AU);",
"     </li>",
"     <li>",
"      Assal (MX);",
"     </li>",
"     <li>",
"      Asthalin (IN);",
"     </li>",
"     <li>",
"      Asthalin HFA (HK);",
"     </li>",
"     <li>",
"      Asthavent (ZA);",
"     </li>",
"     <li>",
"      Asvimol (PH);",
"     </li>",
"     <li>",
"      Avedox-FC (MX);",
"     </li>",
"     <li>",
"      Azmacon (ID);",
"     </li>",
"     <li>",
"      Bajapres (CO);",
"     </li>",
"     <li>",
"      Bemin (EC);",
"     </li>",
"     <li>",
"      Bronchosol (TH);",
"     </li>",
"     <li>",
"      Broncolin (MY, PH);",
"     </li>",
"     <li>",
"      Broncovaleas (IT);",
"     </li>",
"     <li>",
"      Brusal (MX);",
"     </li>",
"     <li>",
"      Brytolin (PH);",
"     </li>",
"     <li>",
"      Butamol (AU);",
"     </li>",
"     <li>",
"      Butavent (MY);",
"     </li>",
"     <li>",
"      Buto-Asma (ES, TH);",
"     </li>",
"     <li>",
"      Butotal (CN);",
"     </li>",
"     <li>",
"      Buventol (AT, CZ, NO, SG, TW);",
"     </li>",
"     <li>",
"      Buventol Easyhaler (FR, TH);",
"     </li>",
"     <li>",
"      Cybutol (ID);",
"     </li>",
"     <li>",
"      Easyhaler Salbutamol (GB, IE);",
"     </li>",
"     <li>",
"      Epaq Inhaler (AU);",
"     </li>",
"     <li>",
"      Farcolin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Grafalin (ID);",
"     </li>",
"     <li>",
"      Hivent DS (PH);",
"     </li>",
"     <li>",
"      Huma-Salmol (HU);",
"     </li>",
"     <li>",
"      Inbumed (MX);",
"     </li>",
"     <li>",
"      Libretin (PH);",
"     </li>",
"     <li>",
"      Medolin (SG);",
"     </li>",
"     <li>",
"      Provexel NS (PH);",
"     </li>",
"     <li>",
"      Respolin (NZ);",
"     </li>",
"     <li>",
"      Salamol (MY);",
"     </li>",
"     <li>",
"      Salbetol (IN);",
"     </li>",
"     <li>",
"      Salbron (ID);",
"     </li>",
"     <li>",
"      Salbuflo (PH);",
"     </li>",
"     <li>",
"      Salbulin (LU);",
"     </li>",
"     <li>",
"      Salbutalan (MX);",
"     </li>",
"     <li>",
"      Salbutamol (HU);",
"     </li>",
"     <li>",
"      Salbutamol-GW (HU);",
"     </li>",
"     <li>",
"      Salbutan (VE);",
"     </li>",
"     <li>",
"      Salbutin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Salbutol (KP);",
"     </li>",
"     <li>",
"      Salbutron SR (KP);",
"     </li>",
"     <li>",
"      Salbuven (ID);",
"     </li>",
"     <li>",
"      Salbuvent (PE);",
"     </li>",
"     <li>",
"      Salmaplon (IN);",
"     </li>",
"     <li>",
"      Salomol (TW);",
"     </li>",
"     <li>",
"      Solia (TH);",
"     </li>",
"     <li>",
"      Sultanol (AT, DE, JP);",
"     </li>",
"     <li>",
"      Teoden (BR);",
"     </li>",
"     <li>",
"      Unibron (MX);",
"     </li>",
"     <li>",
"      Venalax (PH);",
"     </li>",
"     <li>",
"      Venderol (SG);",
"     </li>",
"     <li>",
"      Venetlin (JP);",
"     </li>",
"     <li>",
"      Venterol (TH);",
"     </li>",
"     <li>",
"      Venteze (ZA);",
"     </li>",
"     <li>",
"      Ventilan (CO, PT);",
"     </li>",
"     <li>",
"      Ventilastin Novolizer (DE, FR);",
"     </li>",
"     <li>",
"      Ventodisk (LU);",
"     </li>",
"     <li>",
"      Ventol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ventolin (AE, AR, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CY, CZ, DO, EC, EE, EG, ET, GH, GM, GN, GT, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PK, PL, PR, PY, QA, RU, SA, SC, SD, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Ventolin CFC-Free (AU);",
"     </li>",
"     <li>",
"      Ventoline (DK, FI, FR, NO, SE);",
"     </li>",
"     <li>",
"      Volmax (AE, BH, CY, EC, EG, HU, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Zenmolin (AE, BH, CY, EG, HK, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Zibil (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F130938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relaxes bronchial smooth muscle by action on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors with little effect on heart rate",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F130957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Nebulization/oral inhalation: 0.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     CFC-propelled albuterol: 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Ventolin&reg; HFA: 25 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Oral: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Nebulization/oral inhalation: 3-4 hours; Oral: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to an inactive sulfate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Inhalation: 3.8 hours; Oral: 3.7-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (30% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartfield JM, Boenau IB, Lozon J, et al, &ldquo;Comparison of Metered Dose Inhaler and Oral Administration of Albuterol in the Outpatient Treatment of Infants and Children,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1995, 13(3):375-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/7755840/pubmed\" id=\"7755840\" target=\"_blank\">",
"        7755840",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boulton DW, Fawcett JP, and Fiddes TM, \"Transplacental Distribution of Salbutamol Enantiomers at Caesarian Section,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      ,1997, 44(6):587-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/9431837/pubmed\" id=\"9431837\" target=\"_blank\">",
"        9431837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cook P, Scarfone RJ, and Cook RT, &ldquo;Adenosine in the Termination of Albuterol-Induced Supraventricular Tachycardia,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1994, 24(2):316-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/8037401/pubmed\" id=\"8037401\" target=\"_blank\">",
"        8037401",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Finnerty JP and Howarth PH, &ldquo;Paradoxical Bronchoconstriction With Nebulized Albuterol but not With Terbutaline,&rdquo;",
"      <i>",
"       Am Rev Respir Dis",
"      </i>",
"      , 1993, 148(2):512-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/8342917/pubmed\" id=\"8342917\" target=\"_blank\">",
"        8342917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katz RW, Kelly HW, Crowley MR, et al, &ldquo;Safety of Continuous Nebulized Albuterol for Bronchospasm in Infants and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 92(5):666-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/8414852/pubmed\" id=\"8414852\" target=\"_blank\">",
"        8414852",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leikin JB, Linowiecki KA, Soglin DF, et al, &ldquo;Hypokalemia After Pediatric Albuterol Overdose: A Case Series,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1994, 12(1):64-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/8285977/pubmed\" id=\"8285977\" target=\"_blank\">",
"        8285977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lin R, Smith AJ, and Hergenroeder P, &ldquo;High Serum Albuterol Levels and Tachycardia in Adult Asthmatics Treated With High-Dose Continuously Aerosolized Albuterol,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1993, 103(1):221-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/8417883/pubmed\" id=\"8417883\" target=\"_blank\">",
"        8417883",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahajan M, Tucker J, and Dolgin J, &ldquo;Protocol for Management of Accidental Pediatric Albuterol Ingestions,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36:361.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manthous CA, Hall JB, Schmidt GA, et al, &ldquo;Metered-Dose Inhaler Versus Nebulized Albuterol in Mechanically Ventilated Patients,&rdquo;",
"      <i>",
"       Am Rev Respir Dis",
"      </i>",
"      , 1993, 148(6 Pt 1):1567-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/8256902/pubmed\" id=\"8256902\" target=\"_blank\">",
"        8256902",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marik P, Hogan J, and Krikorian J, &ldquo;A Comparison of Bronchodilator Therapy Delivered by Nebulization and Metered-Dose Inhaler in Mechanically Ventilated Patients,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1999, 115(6):1653-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/10378564/pubmed\" id=\"10378564\" target=\"_blank\">",
"        10378564",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics - 2002,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2002, 110(5 Suppl):141-219.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/12542074/pubmed\" id=\"12542074\" target=\"_blank\">",
"        12542074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP) Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Callaghan C, Milner AD, and Swarbrick A, &ldquo;Nebulized Salbutamol Does Have a Protective Effect on Airways in Children Under One Year Old,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1988, 63(5):479-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/3389861/pubmed\" id=\"3389861\" target=\"_blank\">",
"        3389861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Papo MC, Frank J, and Thompson AE, &ldquo;A Prospective, Randomized Study of Continuous Versus Intermittent Nebulized Albuterol for Severe Status Asthmaticus in Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1993, 21(10):1479-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/8403956/pubmed\" id=\"8403956\" target=\"_blank\">",
"        8403956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rachelefsky GS and Siegel SC, &ldquo;Asthma in Infants and Children - Treatment of Childhood Asthma: Part II,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1985, 76(3):409-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/2863296/pubmed\" id=\"2863296\" target=\"_blank\">",
"        2863296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuh S, Parkin P, Rajan A, et al, &ldquo;High- Versus Low-Dose, Frequently Administered, Nebulized Albuterol in Children With Severe, Acute Asthma,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1989, 83(4):513-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/2927990/pubmed\" id=\"2927990\" target=\"_blank\">",
"        2927990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuh S, Reider MJ, Canny G, et al, &ldquo;Nebulized Albuterol in Acute Childhood Asthma: Comparison of Two Doses,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(4):509-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/2216613/pubmed\" id=\"2216613\" target=\"_blank\">",
"        2216613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spiller HA, Ramoska EA, Henretig FM, et al, &ldquo;A Two-Year Retrospective Study of Accidental Pediatric Albuterol Ingestions,&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 1993, 9(6):338-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/8302698/pubmed\" id=\"8302698\" target=\"_blank\">",
"        8302698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Udezue E, D'Souza L, and Mahajan M, &ldquo;Hypokalemia After Normal Doses of Nebulized Albuterol (Salbutamol),&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1995, 13(2):168-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/7893301/pubmed\" id=\"7893301\" target=\"_blank\">",
"        7893301",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiley JF 2nd, Spiller HA, Krenzelok EP, et al, &ldquo;Unintentional Albuterol Ingestion in Children,&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 1994, 10(4):193-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/61/16344/abstract-text/7937293/pubmed\" id=\"7937293\" target=\"_blank\">",
"        7937293",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9396 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16344=[""].join("\n");
var outline_f15_61_16344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130976\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130977\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131027\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130981\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131004\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130982\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130983\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671334\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130951\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950005\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130935\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130955\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5167761\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130954\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131035\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131025\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130958\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130939\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298694\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130944\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130971\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130947\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130961\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130987\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16137852\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130962\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130960\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130949\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130963\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130938\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130957\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9396\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9396|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/50/40741?source=related_link\">",
"      Albuterol (salbutamol): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=related_link\">",
"      Albuterol (salbutamol): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_61_16345="Refractory or recurrent peptic ulcer disease";
var content_f15_61_16345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Refractory or recurrent peptic ulcer disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/61/16345/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/61/16345/contributors\">",
"     Andrew H Soll, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/61/16345/contributors\">",
"     Nimish B Vakil, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/61/16345/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/61/16345/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/61/16345/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/61/16345/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/61/16345/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most peptic ulcers respond to treatment with antimicrobial therapy for Helicobacter pylori, withdrawal of NSAIDs, or to treatment with potent antisecretory drugs. However, in some individuals, the ulcer is either refractory to conventional therapy, or recurs following successful initial treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The same overlapping set of factors underlies ulcers that fail to heal or that recur (",
"    <a class=\"graphic graphic_table graphicRef76314 \" href=\"UTD.htm?5/23/5501\">",
"     table 1",
"    </a>",
"    ). The most important aspect of the assessment of such ulcers is to discriminate several elements that may influence natural history:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of factors that perpetuate the ulcer itself, such as gastric hypersecretion due to gastrinoma, failed H. pylori detection or eradication, undiscovered or undisclosed occult continued use of NSAIDs, severe local scarring that retards healing, and comorbid disease.",
"     </li>",
"     <li>",
"      Pathology that mimics ulcer disease, such as carcinoma.",
"     </li>",
"     <li>",
"      Refractory symptoms in the absence of refractory ulceration, which are often part of a functional GI or somatoform disorder.",
"     </li>",
"     <li>",
"      Poor patient compliance or true resistance to secretory inhibition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REFRACTORY ULCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the H2 receptor antagonist (H2RA) era, ulcers were considered refractory if healing was not evident after eight weeks of therapy, with the time frame adjusted somewhat for ulcer size [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/1\">",
"     1",
"    </a>",
"    ]. Ulcer management has undergone revolutionary change, and ulcers refractory to H2RA are substantially different from ulcers refractory to current management. However, eight weeks remains a reasonable period to define refractory ulceration.",
"   </p>",
"   <p>",
"    Much more rapid ulcer healing can be anticipated with proton pump inhibitors (PPI), with successful cure of H. pylori, or removal of NSAIDs, as appropriate. Slower healing should be anticipated for a variety of reasons, such as large ulcer size, a history of complications (such ulcers are often deep), or ulcers associated with scarring or deformity, persisting NSAID or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    H. pylori infection, or ongoing inflammation from another cause.",
"   </p>",
"   <p>",
"    Interestingly, the natural history of refractory peptic ulcer disease may have changed in the last several decades. An illustrative study described 4032 DU patients who were treated in a consistent fashion with H2RA over a period from 1976 to 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/2\">",
"     2",
"    </a>",
"    ]. Overall, 19 percent were refractory, as defined by persistent ulceration at endoscopy after 12 weeks of treatment. The remarkable observation was that the incidence of refractory DU fell in a linear fashion from 33 percent in 1976 to 1978 to 7 percent in 1989 to 1993. This study was conducted before PPI and H. pylori treatment became routine in this single hospital conducting the trial. These data suggest that there has been change in the natural history of peptic ulcer. However, there are no other known large data sets that allow this hypothesis to be tested or mechanisms to be defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Refractory symptoms versus ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential to differentiate between refractory symptoms and refractory ulceration. Endoscopy discriminates patients with intractable symptoms associated with a refractory ulcer from those with intractable symptoms without active ulceration. Persistent symptoms in the absence of an active ulcer on endoscopy suggest that other etiologies for the symptoms should be sought.",
"   </p>",
"   <p>",
"    Two lines of evidence suggest that symptoms in patients with refractory peptic ulcer often reflect more than acid bathing an unhealed ulcer crater:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with refractory ulcers are more likely to return with symptoms even after their ulcers have been healed. This was illustrated in a surgical series of patients who underwent highly selective vagotomy for refractory ulcers that never responded adequately to medical management; only 3 percent of patients developed an ulcer recurrence while 41 percent returned for recurrent symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/3\">",
"       3",
"      </a>",
"      ]. In contrast, the patients who underwent surgery for recurrent, but not refractory, ulcers had a 5 percent recurrence of ulcers and only an 11 percent recurrence of symptoms.",
"     </li>",
"     <li>",
"      Symptoms in DU patients often include more than classic acid dyspepsia (hunger pain with relief occurring when acid is buffered with food or antacids or inhibited by antisecretory agents) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/4\">",
"       4",
"      </a>",
"      ]. Ulcer patients also frequently complain of symptoms of acid reflux or an irritable stomach (causing indigestion-like symptoms without gastric retention). There can also be considerable overlap with irritable bowel syndrome (IBS). A relation between IBS and dyspepsia was also found in a population-based longitudinal survey in Sweden, which evaluated questionnaires sent to 1290 individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/5\">",
"       5",
"      </a>",
"      ]. The prevalence of dyspepsia was 14 percent (32 percent if predominant reflux symptoms and concomitant IBS symptoms were included) and the prevalence of IBS was 12.5 percent. However, among patients with IBS, 87 percent also fulfilled the dyspepsia criteria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"       \"Approach to the patient with dyspepsia\"",
"      </a>",
"      .) Although systematic surveys of ulcer patients are limited, approximately 30 to 50 percent experience symptoms in addition to or other than classic acid dyspepsia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanisms accounting for symptoms unrelated to active ulceration have not been defined. However, sensitization of afferent nerves by inflammatory or infectious tissue insults, such as H. pylori gastritis or peptic ulcer, is an attractive hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, induction of an \"irritable gut\" may underlie refractory symptoms or symptoms other than acid dyspepsia in a subset of patients.",
"   </p>",
"   <p>",
"    On the other hand, the absence of symptoms does not exclude the presence of a persisting ulcer crater. At least 25 percent of refractory ulcers are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Conditions underlying refractory ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following factors should be considered when confronted with refractory peptic ulceration (",
"    <a class=\"graphic graphic_table graphicRef76314 \" href=\"UTD.htm?5/23/5501\">",
"     table 1",
"    </a>",
"    ). These same factors will also underlie recurrent ulceration described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Persistent H. pylori infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful cure of H. pylori predicts rapid healing in most refractory (as well as unselected) ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Curing H. pylori enhances healing rates even in patients with ulcers that are refractory to antisecretory therapy; exceptions reflect other factors, such as concomitant, continued NSAID or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use or acid hypersecretion.",
"   </p>",
"   <p>",
"    In a study of 333 consecutive patients with H. pylori, healing was 12 times more likely with successful cure of H. pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/10\">",
"     10",
"    </a>",
"    ]. A study of 42 H. pylori-positive DU patients refractory to H2RA compared four weeks of colloidal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    subcitrate and two weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    to an eight week course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    (40 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/12\">",
"     12",
"    </a>",
"    ]. All 21 patients randomized to triple therapy were healed at the end of treatment, compared to only 12 of 17 in the omeprazole group. Another study of H. pylori infected, refractory DU patients found that healing occurred in 30 of 43 patients (70 percent) of patients during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    plus antimicrobials, versus 6 of 28 patients (21 percent) treated with cimetidine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, cure of H. pylori is not universally effective in healing ulcers and preventing recurrence; the outcome depends on whether there are additional factors that are contributing to the ulcer diathesis. As an example, cure of H. pylori in patients continuing NSAIDs or with concomitant acid hypersecretion may not prevent recurrent ulcer development. Ulcer recurrence despite H. pylori treatment may also be increased in the presence of uremia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persistent H. pylori can underlie refractory peptic ulceration, either because it was not initially recognized or not treated due to a false-negative test, or because the organism was not eradicated with the administered antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/11\">",
"     11",
"    </a>",
"    ]. The latter situation is most likely to occur due to selection of an inappropriate regimen, antibiotic resistance (particularly to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ), or poor patient compliance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urea breath and stool antigen testing are the noninvasive tests of choice to confirm eradication of H. pylori, although the sensitivity for detecting infection is only about 90 percent. If the urea breath or stool antigen test is positive, specificity is adequate to confidently justify repeat antibiotic treatment. For uncomplicated cases, negative urease breath testing is adequate to exclude persistent infection, although a 10 percent failure rate must be kept in mind. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, for refractory or complicated cases, a strong argument can be made to perform endoscopy to ensure that the ulcer has healed and to confidently exclude persisting H. pylori infection. If the patient has been off antibiotics and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    for four weeks and PPI for one to two weeks, it is reasonable to first perform urease testing on biopsies (eg, the CLO test) because of the low cost, good sensitivity (90 percent) and high specificity (&gt;95 percent). Histology should be reserved for urease-negative cases to detect inflammation and organisms. This strategy ensures ulcer healing and confidently excludes persisting H. pylori infection in cases with a history of troublesome ulcers. Endoscopy also provides the option for culture and assessing antibiotic resistance when resistance is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuing nonsteroidal antiinflammatory drug (NSAID) use is a critical factor underlying a surprising number of refractory ulcers. Patients may not admit to use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and NSAIDs, even after experiencing ulcer recurrences, a refractory course, or undergoing surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/11,14,15\">",
"     11,14,15",
"    </a>",
"    ]. An illustrative study included 60 patients with refractory peptic ulcer and 54 nonrefractory matched controls. NSAID and analgesic abuse were the most significant factors associated with refractoriness, present in 40 percent of those with nonhealing ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/11\">",
"     11",
"    </a>",
"    ]. Forty-four percent of NSAID use was initially denied by the patient and only discovered by measuring platelet cyclooxygenase activity. It is essential to rule out continued NSAID use or abuse in all patients with refractory or recurrent ulcers. This evaluation should include measurement of serum salicylate levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Large ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large and small GU heal at the same rate on antacids, approximately 3 mm per week [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, larger ulcers will require more time to heal. Ulcer size also impacts healing rates for DU. In one study, for example, three risk factors were related to nonhealing of DU at four weeks: prior ulcer history; ulcer size; and smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/17\">",
"     17",
"    </a>",
"    ]. Ulcer healing was less likely in ulcers &ge;10 mm in diameter (62 versus 76 percent with smaller ulcers). Big ulcers also are often densely scarred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective antiulcer therapy usually compensates for the deleterious effects of smoking on ulcer healing. However, cigarette smoking, particularly if heavy, may contribute to impaired healing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Impaired healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a subset of patients, refractory ulcers may be explained by poor healing because of factors such as an intense inflammatory response, dense scarring, or low mucosal blood flow, which would impair angiogenesis and tissue repair. The same factors that result in poor initial healing will promote rapid recurrence (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Recurrent ulcers'",
"    </a>",
"    below). Several factors have been hypothesized to underlie poor healing. As an example, in one study approximately one-half of patients with a poorly healing gastric ulcer had low or absent TGF-beta or its receptor, suggesting that impaired TGF-beta action may result in delayed healing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/18\">",
"     18",
"    </a>",
"    ]. Further studies are needed to confirm these observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Acid hypersecretory states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional cases of refractory DU are due to gastrinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/19\">",
"     19",
"    </a>",
"    ]. In nongastrinoma refractory DU, increased basal, nocturnal, and maximal acid secretion may be a contributing factor in a subset of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. One study, for example, examined the basal acid output of 75 patients with DU [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/22\">",
"     22",
"    </a>",
"    ]. Fifty-five patients who had complete healing of their ulcer had a mean basal acid output of 6.6",
"    <span class=\"nowrap\">",
"     mEq/hour,",
"    </span>",
"    while 20 patients with nonhealing DU had a mean basal acid output of 20.0",
"    <span class=\"nowrap\">",
"     mEq/hour.",
"    </span>",
"    The patients with nonhealing ulcers were treated with increased doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    (mean 675",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    range 600 to 1200",
"    <span class=\"nowrap\">",
"     mg/day);",
"    </span>",
"    all had complete healing on endoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Furthermore, healing rates for DU, and to a lesser extent GU, correlate well with the degree of inhibition of acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The study of 333 consecutive H. pylori-positive ulcer patients mentioned above [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/10\">",
"     10",
"    </a>",
"    ] also found that atrophic gastritis predicted enhanced healing, an effect presumably due to lower levels of acid secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Impaired response to antisecretory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tolerance to H2 receptor antagonists that develops during sustained therapy has been hypothesized to contribute to some cases of refractory ulcers in response to these agents. Similar tolerance does not seem to develop with PPIs. For the occasional patient who fails to respond to standard doses of PPI, double doses are usually effective in inducing and maintaining healing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/1\">",
"     1",
"    </a>",
"    ]. Rapid P450 mediated metabolism probably accounts for some of the patients who respond poorly to PPI. Other mechanisms of PPI resistance are rare and still poorly defined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=see_link\">",
"     \"Approach to refractory gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Comorbid diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbid diseases such as uremia, respiratory failure, cirrhosis, and a chronic catabolic state due to any number of diseases can promote ulcer formation and complications and impair healing. The study described above underlines the point that uremic patients were more likely to have ulcer recurrences after successful cure of H. pylori compared to non-uremic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/13\">",
"     13",
"    </a>",
"    ]. Concurrent therapy with certain drugs, such as corticosteroids, cytotoxic agents, and cocaine, may also contribute to ulcerogenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"     \"Unusual causes of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8366970\">",
"    <span class=\"h3\">",
"     Emotional stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several lines of evidence indicating that psychological factors and poorly-tolerated stress in particular increase the occurrence of peptic ulcer disease. The impact of psychological factors on ulcer recurrence and the response to healing has received very limited attention; therefore, one can only surmise that psychological factors warrant consideration in patients with recurrent or refractory ulcer disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3658?source=see_link&amp;anchor=H18#H18\">",
"     \"Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis\", section on 'Psychologic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19608022\">",
"    <span class=\"h3\">",
"     Unusual causes of refractory ulceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an ulcer is refractory and after H. pylori and NSAIDs have been excluded, unusual causes of peptic ulceration that range from gastrinoma to uncommon infections and inflammatory conditions should be considered (",
"    <a class=\"graphic graphic_table graphicRef76314 \" href=\"UTD.htm?5/23/5501\">",
"     table 1",
"    </a>",
"    ). The latter includes entities such as eosinophilic gastroenteritis that can affect all ages and can occur in the absence of marked eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/25-27\">",
"     25-27",
"    </a>",
"    ], as well as a sclerosing, IgG4-positive inflammatory process associated with refractory GU and autoimmune pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/28\">",
"     28",
"    </a>",
"    ]. As endoscopic submucosal dissection and endoscopic mucosal resection are increasingly used for the management of early gastric cancer, iatrogenic ulcers are created and can be difficult to manage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful clinical evaluation is critical to seek evidence of other functional or organic processes that could account for persistent symptoms. Endoscopy is necessary to determine if these symptoms are linked to refractory ulceration;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    contrast radiography cannot confidently assess ulcer healing or exclude other disease processes since the accuracy of radiography is compromised in the setting of edema, spasm, or a deformed duodenal bulb. These factors can also compromise the sensitivity of endoscopy, especially in inexperienced hands. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24919?source=see_link\">",
"     \"Diagnosis of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If recurrent ulceration is found, biopsies of the antrum and body are indicated to diagnose or exclude H. pylori and chronic active gastritis. Importantly, such patients are frequently on a PPI, which may lead to false negative results on H. pylori tests that depend upon the number of organisms (ie, culture, rapid urease test on biopsies, urea breath test, detection of bacteria by histology, and stool antigen test). Thus, if a negative test is obtained for a patient on a PPI, it should be confirmed with additional testing, ideally with the patient off the PPI for at least two weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Refractory ulcers in the absence of chronic active gastritis should prompt further consideration of NSAID use and hypersecretory states, in particular.",
"   </p>",
"   <p>",
"    There are several reasons to perform multiple biopsies of the margin and base of refractory GU, the most important of which is to exclude neoplasia. Benign-appearing and biopsy-negative ulcers can still harbor carcinoma, and non-healing GU must be considered cancer until proven otherwise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\"",
"    </a>",
"    .) In addition, as noted above, several infectious and inflammatory conditions can mimic refractory peptic ulcer, warranting biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"     \"Unusual causes of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fasting serum gastrin should be measured to exclude gastrinoma and antral G cell hyperfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/19\">",
"     19",
"    </a>",
"    ], but caution is necessary because both PPI and H. pylori can raise gastrin levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The location of the refractory ulcer dictates the approach. The risk of neoplasia warrants aggressive biopsy for refractory GU, whereas with refractory DU the risk of neoplasia is very low, but not zero. An isolated refractory GU is unlikely to be due to acid hypersecretion, whereas post-bulbar duodenal ulcers warrant careful exclusion of acid hypersecretion that may occur in the presence or absence of gastrinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eradication of H. pylori, if present, facilitates healing and decreases the otherwise high recurrence expected with refractory ulcers. As noted, NSAID use should be diligently sought and stopped whenever possible. In patients with endoscopic ulcers related to NSAID use that were not refractory to prior treatment, antisecretory agents do induce healing after eight weeks even with continued NSAID use [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Antisecretory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with refractory peptic ulcers who are not infected with H. pylori, potent antisecretory therapy is warranted. Patients who fail to respond to H2 receptor antagonists are likely to benefit from treatment with a PPI, especially if given in an adequate dose. This was illustrated in a study that randomly assigned patients with unhealed DU after six weeks of H2 receptor antagonist therapy to subsequent therapy with a relatively low dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or continued therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    (150 mg twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/30\">",
"     30",
"    </a>",
"    ]. Both regimens produced about 70 percent healing after four weeks, indicating that 20 mg of omeprazole may not be an optimal dose for refractory ulcers. In a second report of patients with refractory ulcers after three months of H2 receptor antagonist therapy, a 40 mg dose of omeprazole produced better healing than continued standard H2 receptor antagonist therapy (96 versus 57 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, omeprazole heals ulcers refractory to standard doses of H2 receptor antagonists; a 40 mg dose appears to be necessary to achieve a predictable advantage.",
"   </p>",
"   <p>",
"    No controlled trials are available to guide the approach to refractory GU. However, uncontrolled trials suggest that a 40 mg daily dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    or a 30 mg dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    are effective in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/1,31\">",
"     1,31",
"    </a>",
"    ]. Endoscopy is indicated after eight weeks of additional treatment, as are multiple biopsies to exclude malignancy. Biopsies are a reasonable caution for refractory GU that have healed, since some neoplastic ulcers can heal with powerful antisecretory therapy.",
"   </p>",
"   <p>",
"    The ability of a 40 mg daily dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    to heal most refractory ulcers suggests that reliable healing requires profound acid inhibition. Direct measurement of gastric acid output or pH may be useful for patients who are not responding to therapy or who need prolonged therapy. The optimal degree of inhibition of acidity or acid output remains undefined; nevertheless, healing of DU is likely to occur if the gastric pH is above 4 for 90 percent of the day [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition to reducing acid exposure, maintenance of a high pH minimizes pepsin generation and reduces the activity of pepsin; this is an important effect because acid plus pepsin is much more ulcerogenic than acid alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/32\">",
"     32",
"    </a>",
"    ]. Conversely, if the pH is below 2 for most of the day, the patient is clearly not responding well to antisecretory therapy and an adjustment is necessary. Unless the underlying cause is reversed, refractory ulcers tend to readily recur after antisecretory therapy is discontinued or decreased to \"maintenance\" levels.",
"   </p>",
"   <p>",
"    Judging the appropriate length of continued antisecretory therapy for refractory ulcers is an empiric process that must be adapted to the individual patient. If the underlying cause can be reversed, then treatment usually becomes easy. If NSAIDs can be removed, for example, healing usually can be readily accomplished and maintenance therapy may not be necessary. For H. pylori-associated refractory ulcers, sustained full dose antisecretory therapy is appropriate until cure of the infection can be confirmed. However, for both refractory H. pylori and NSAID-induced ulcers where the cause has been removed, a period (6 to 24 months) of sustained full dose antisecretory therapy is a reasonable caution particularly for large or densely scarred ulcers. Sustained full dose therapy may be necessary for an indefinite period when the cause of the ulcer cannot be reversed.",
"   </p>",
"   <p>",
"    There is no evidence to support the efficacy of combination H2 receptor antagonist and PPI therapy in patients with refractory peptic ulcer. The effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    could be compromised by simultaneous use with other antisecretory agents since acidic compartments within the activated parietal cell are required for activation of PPI. The role of adding nighttime H2RA to daytime PPI to control nocturnal breakthrough has not been tested for refractory ulcers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=see_link\">",
"     \"Pharmacology of antiulcer medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective surgery for peptic ulcer is increasingly uncommon in current practice. However, excessive reliance upon pharmacotherapy, reluctance to admit failure of medical or endoscopic management, and an exaggerated fear of the consequences of surgical intervention may delay an appropriate operation. Such a delay could convert a potentially elective or semielective situation into an emergent one, with an attendant increase in perioperative morbidity and mortality.",
"   </p>",
"   <p>",
"    Reversible risk factors need to be addressed, as noted above, before offering elective surgery. In particular, H. pylori infection must be cured and NSAID use confidently excluded. As previously mentioned, it is also essential to confirm that intractable symptoms are associated with refractory ulceration, since many symptomatic patients with an ulcer history have symptoms due to causes other than active peptic ulcer disease (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Refractory symptoms versus ulcers'",
"    </a>",
"    above). Persistence of symptoms following healing of ulcers should prompt a search for other mechanisms underlying symptoms, rather than surgery.",
"   </p>",
"   <p>",
"    Patients who fail to respond to medical management may also pose a greater risk for failing surgical management, although this is controversial. One report (from the era before the importance of H. pylori and NSAIDs was recognized) examined 157 patients who had a highly selective vagotomy for uncomplicated duodenal ulcer: in 57, the ulcer had failed to heal despite treatment with H2 receptor antagonists (refractory group); 19 had developed recurrent ulceration while receiving maintenance treatment; 67 had remained healed while taking H2 receptor antagonists but suffered frequent relapses when treatment was discontinued; and 14 had not been given these drugs before surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/33\">",
"     33",
"    </a>",
"    ]. The incidence of recurrent ulceration at two and five years was 18 and 34 percent in the refractory group, versus 1.5 and 3 percent, respectively, in patients whose ulcers had healed with H2 receptor antagonists.",
"   </p>",
"   <p>",
"    In contrast, in a second series of patients undergoing parietal cell vagotomy, there was only one ulcer recurrence in a 24 to 85 month follow-up period among 30 patients who had not responded to preoperative H2 receptor antagonist therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/3\">",
"     3",
"    </a>",
"    ]. The explanation for the differences between these studies is not clear; important factors may include the duration of therapy, type of medical management, and criteria defining \"refractory\" and recurrent ulceration. In light of the dramatic advances in management of ulcer disease, it is essential to pursue potentially curable underlying causes and give maximal medical therapy before recommending elective surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33688?source=see_link\">",
"     \"Role of surgery in the management of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RECURRENT ULCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with refractory peptic ulcers, careful clinical and endoscopic evaluation is essential to differentiate recurrent symptoms from recurrent ulceration. This evaluation should exclude diseases mimicking peptic ulcer (eg, gastric cancer mimicking GU), and causes of peptic ulcer that require specific therapy, such as H. pylori infection, NSAID use, and gastrinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Factors influencing recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The quality of duodenal ulcer healing reflects the degree of restoration of normal epithelial architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/34\">",
"     34",
"    </a>",
"    ]. Marked inflammation, an absence of glandular structure, and blunt or absent villi are markers of poor histologic restoration. This regional inflammatory response and poor healing appear to predispose to duodenal ulcer recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Duodenal bulb deformity, presumably due to dense scarring, and gastric metaplasia in the duodenum have also predicted DU recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. In one study, for example, the recurrence rate in patients with evidence of good histologic healing after therapy was 3.5 percent versus 20 percent in those with a poor histology [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/34\">",
"     34",
"    </a>",
"    ]. Incompletely healed ulcers (no crater but partial epithelialization or hyperemic, friable scars) also have higher recurrence rates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar conclusions probably hold for GU. Most GU recurrences occurring on either placebo or H2 receptor antagonist therapy appear to result from red or incompletely healed scars, compared to white or completely healed scars [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of the factors that influence the development of refractory peptic ulcers also impact ulcer recurrence. NSAID use and H. pylori infection are the most important reversible factors to consider.",
"   </p>",
"   <p>",
"    Recurrence rates are markedly reduced following successful cure of H. pylori infection, although the degree of reduction is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12455?source=see_link\">",
"     \"Management of duodenal ulcers in patients infected with Helicobacter pylori\"",
"    </a>",
"    .) In one study, recurrences were associated with continued high pentagastrin-stimulated peak acid output, rather than reinfection with H. pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/41\">",
"     41",
"    </a>",
"    ]. Once identified, maintenance antisecretory treatment may be necessary to prevent relapse in this subset of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12455?source=see_link\">",
"     \"Management of duodenal ulcers in patients infected with Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors also may be important in determining ulcer recurrence. Patients who have ulcers that readily heal on placebo therapy have a more \"benign\" form of ulcer disease and are less disposed to recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/45\">",
"     45",
"    </a>",
"    ]. On the other hand, the following findings are associated with a higher risk of recurrence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prior history of ulcer complications, such as bleeding or perforation, predicts complicated recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A history of prior frequent recurrences [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/36,46\">",
"       36,46",
"      </a>",
"      ] or ulcers refractory to initial therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. As an example, during a 24 month trial of maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      therapy, there was a 48 percent recurrence rate among patients who initially had refractory ulcers versus 20 percent among those with nonrefractory ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies that were mostly performed in the pre-H. pylori era suggested that smokers had a higher rate of ulcer recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. However, smoking may not be a significant risk factor for recurrence once H. pylori has been eradicated from infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In one report, 256 patients with DU and 31 patients with GU were followed for up to 18 months after ulcer healing and successful eradication of H. pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/52\">",
"     52",
"    </a>",
"    ]. Ulcer relapse occurred in 3 of 83 smokers (3.6 percent) versus 4 of 204 nonsmokers (2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance therapy is indicated to prevent recurrence in high-risk subgroups, defined by a history of complications, frequent recurrences, or refractory, giant, or severely fibrosed ulcers. In patients in the high risk subgroup who are infected with H. pylori, maintenance therapy should be continued at least until cure of the infection and healing of the ulcer have been confirmed. Maintenance therapy is also indicated in high-risk patients who fail H. pylori eradication or who have recurrent H. pylori-negative ulcers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Maintenance therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Breakthrough recurrences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrences have been seen while on maintenance therapy and after eradication of Helicobacter pylori infection.",
"   </p>",
"   <p>",
"    Asymptomatic recurrences account for 25 to 40 percent of recurrences on therapy for both DU and GU [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/46,54,55\">",
"     46,54,55",
"    </a>",
"    ]. Ulcers that occur on maintenance therapy are more likely to be asymptomatic than are recurrences on placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/36,54\">",
"     36,54",
"    </a>",
"    ]. In one study, for example, one-half of recurrences in patients receiving maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    therapy for DU were asymptomatic, compared to 25 percent of those occurring in patients receiving placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asymptomatic recurrences on maintenance therapy only infrequently cause complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16345/abstract/46,54\">",
"     46,54",
"    </a>",
"    ]. Their benign nature does not warrant concern or aggressive intervention (eg, surgery). Thus, in uncomplicated cases, asymptomatic ulcers should not be looked for (once gastric carcinoma has been confidently excluded).",
"   </p>",
"   <p>",
"    When breakthrough recurrences are encountered, reversible causes should be considered (eg, resumption of NSAID use or persisting or recurrent H. pylori infection). Appropriate management includes increasing the antisecretory dose (full dose H2 receptor antagonist) or more likely switching to a PPI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=see_link\">",
"       \"Patient information: Peptic ulcers (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=see_link\">",
"       \"Patient information: H. pylori infection (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"       \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"       \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulcers can be considered refractory if healing is not evident after eight weeks of therapy on PPI.",
"     </li>",
"     <li>",
"      A longer period may be necessary for giant ulcers to heal; one can expect about 2 cm of healing during an eight week period. If this degree of healing is not found, then the causes for refractory healing should be considered.",
"     </li>",
"     <li>",
"      With refractory or recurrent ulcers, persisting H. pylori or NSAID use must be excluded. If ulceration persists after NSAIDs and H. pylori have been eliminated, then endoscopic biopsy is indicated to exclude other benign or malignant diseases.",
"     </li>",
"     <li>",
"      The mainstay of treatment remains use of an adequate PPI regimen, adapted to the patient's clinical response, plus withdrawal of NSAIDs and cure of H. pylori, as indicated. Unless emergent, surgery should be approached cautiously and only after carefully excluding reversible causes. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/1\">",
"      Bardhan KD. Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther 1993; 7 Suppl 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/2\">",
"      Bardhan KD, Nayyar AK, Royston C. History in our lifetime: the changing nature of refractory duodenal ulcer in the era of histamine H2 receptor antagonists. Dig Liver Dis 2003; 35:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/3\">",
"      Goodman AJ, Kerrigan DD, Johnson AG. Effect of the pre-operative response to H2 receptor antagonists on the outcome of highly selective vagotomy for duodenal ulcer. Br J Surg 1987; 74:897.",
"     </a>",
"    </li>",
"    <li>",
"     Soll AH, Graham DY. Peptic ulcer disease. In: Textbook of Gastroenterology, Yamada T (Ed), Wiley-Blackwell, Oxford 2009. p.936.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/5\">",
"      Agr&eacute;us L, Sv&auml;rdsudd K, Nyr&eacute;n O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109:671.",
"     </a>",
"    </li>",
"    <li>",
"     Cervero F, Gebhart GF. Visceral hypersensitivity. In: Functional Pain Syndromes: Presentation and Pathophysiology, Mayer EA, Bushnell MC (Eds), International Association for the Study of Pain, Seattle 2009. p.361.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/7\">",
"      Bianchi Porro G, Parente F. Duodenal ulcers resistant H2 blockers: An emerging therapeutic problem. Scand J Gastroenterol 1988; 23:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/8\">",
"      Boyd HK, Zaterka S, Eisig JN, et al. Helicobacter pylori and refractory duodenal ulcers: cross-over comparison of continued cimetidine with cimetidine plus antimicrobials. Am J Gastroenterol 1994; 89:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/9\">",
"      Mantzaris GJ, Hatzis A, Tamvakologos G, et al. Prospective, randomized, investigator-blind trial of Helicobacter pylori infection treatment in patients with refractory duodenal ulcers. Healing and long-term relapse rates. Dig Dis Sci 1993; 38:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/10\">",
"      Arkkila PE, Kokkola A, Sepp&auml;l&auml; K, Sipponen P. Size of the peptic ulcer in Helicobacter pylori-positive patients: association with the clinical and histological characteristics. Scand J Gastroenterol 2007; 42:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/11\">",
"      Lanas A, Remacha B, S&aacute;inz R, Hirschowitz BI. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy. Am J Gastroenterol 2000; 95:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/12\">",
"      Avsar E, Kalayci C, T&ouml;z&uuml;n N, et al. Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 1996; 8:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/13\">",
"      Tseng GY, Lin HJ, Fang CT, et al. Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication: a 2-year study. Aliment Pharmacol Ther 2007; 26:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/14\">",
"      Hirschowitz BI, Lanas A. Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. Gastroenterology 1998; 114:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/15\">",
"      Hirschowitz BI, Lanas A. Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse. J Clin Gastroenterol 2002; 34:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/16\">",
"      STEIGMANN F, SHULMAN B. The time of healing of gastric ulcers: implications as to therapy. Gastroenterology 1952; 20:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/17\">",
"      Reynolds JC, Schoen RE, Maislin G, Zangari GG. Risk factors for delayed healing of duodenal ulcers treated with famotidine and ranitidine. Am J Gastroenterol 1994; 89:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/18\">",
"      Shih SC, Tseng KW, Lin SC, et al. Expression patterns of transforming growth factor-beta and its receptors in gastric mucosa of patients with refractory gastric ulcer. World J Gastroenterol 2005; 11:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/19\">",
"      Annibale B, De Magistris L, Corleto V, et al. Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease. Aliment Pharmacol Ther 1994; 8:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/20\">",
"      Walt RP, Daneshmend TK. Resistant duodenal ulcer: when, why and what to do? Postgrad Med J 1988; 64:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/21\">",
"      Bianchi Porro G, Lazzaroni M, Barbara L, et al. Tripotassium dicitrate bismuthate and ranitidine in duodenal ulcer. Healing and influence on recurrence. Scand J Gastroenterol 1988; 23:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/22\">",
"      Collen MJ, Stanczak VJ, Ciarleglio CA. Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication). Dig Dis Sci 1989; 34:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/23\">",
"      Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/24\">",
"      Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther 1990; 4:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/25\">",
"      Park TY, Choi CH, Yang SY, et al. A case of hypereosinophilic syndrome presenting with intractable gastric ulcers. World J Gastroenterol 2009; 15:6129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/26\">",
"      Tee HP, Swartz D, Tydd T, Leong RW. Gastrointestinal: Eosinophilic enteritis manifesting as brown-pigmented duodenal ulcers. J Gastroenterol Hepatol 2009; 24:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/27\">",
"      Siaw EK, Sayed K, Jackson RJ. Eosinophilic gastroenteritis presenting as acute gastric perforation. J Pediatr Gastroenterol Nutr 2006; 43:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/28\">",
"      Fujita T, Ando T, Sakakibara M, et al. Refractory gastric ulcer with abundant IgG4-positive plasma cell infiltration: a case report. World J Gastroenterol 2010; 16:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/29\">",
"      Goldstein JL, Johanson JF, Hawkey CJ, et al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther 2007; 26:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/30\">",
"      Delchier JC, Isal JP, Eriksson S, Soule JC. Double blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers. Gut 1989; 30:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/31\">",
"      van Rensburg CJ, Louw JA, Girdwood AH, et al. A trial of lansoprazole in refractory gastric ulcer. Aliment Pharmacol Ther 1996; 10:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/32\">",
"      Samloff IM. Peptic ulcer: the many proteinases of aggression. Gastroenterology 1989; 96:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/33\">",
"      Primrose JN, Axon AT, Johnston D. Highly selective vagotomy and duodenal ulcers that fail to respond to H2 receptor antagonists. Br Med J (Clin Res Ed) 1988; 296:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/34\">",
"      Pan SA, Liao CH, Lien GS, Chen SH. Histological maturity of healed duodenal ulcers and ulcer recurrence after treatment with colloidal bismuth subcitrate or cimetidine. Gastroenterology 1991; 101:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/35\">",
"      Moshal MG, Gregory MA, Pillay C, Spitaels JM. Does the duodenal cell ever return to normal? A comparison between treatment with cimetidine and denol. Scand J Gastroenterol Suppl 1979; 54:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/36\">",
"      Van Deventer GM, Elashoff JD, Reedy TJ, et al. A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer. N Engl J Med 1989; 320:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/37\">",
"      Piai G, Sabbatini F, Minieri M, et al. The influence of severe bulb deformity on duodenal ulcer relapse. Hepatogastroenterology 1990; 37:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/38\">",
"      Chang CC, Pan S, Lien GS, et al. Deformity of duodenal bulb, gastric metaplasia of duodenal regenerating mucosa and recurrence of duodenal ulcer: a correlated study. World J Gastroenterol 2005; 11:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/39\">",
"      Paoluzi P, Pallone F, Zaccardelli E, et al. Outcome of ulcer-associated duodenitis after short-term medical treatment. Dig Dis Sci 1985; 30:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/40\">",
"      Takemoto T, Namiki M, Ishikawa M, et al. Ranitidine and sucralfate as maintenance therapy for gastric ulcer disease: endoscopic control and assessment of scarring. Gut 1989; 30:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/41\">",
"      Harris AW, Gummett PA, Phull PS, et al. Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output. Aliment Pharmacol Ther 1997; 11:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/42\">",
"      Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/43\">",
"      Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/44\">",
"      Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/45\">",
"      Frederiksen HJ, Matzen P, Madsen P, et al. Spontaneous healing of duodenal ulcers. Scand J Gastroenterol 1984; 19:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/46\">",
"      Penston JG, Wormsley KG. Review article: maintenance treatment with H2-receptor antagonists for peptic ulcer disease. Aliment Pharmacol Ther 1992; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/47\">",
"      Jensen DM, Cheng S, Kovacs TO, et al. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med 1994; 330:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/48\">",
"      Str&ouml;m M, Bodemar G, Gotthard R, Walan A. Duodenal, prepyloric, and combined duodenal/prepyloric ulcer disease: three distinct entities of juxtapyloric ulcer disease? Scand J Gastroenterol 1986; 21:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/49\">",
"      Bardhan KD, Hinchliffe RF, Bose K. Low dose maintenance treatment with cimetidine in duodenal ulcer: intermediate-term results. Postgrad Med J 1986; 62:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/50\">",
"      Martin DF, Montgomery E, Dobek AS, et al. Campylobacter pylori, NSAIDS, and smoking: risk factors for peptic ulcer disease. Am J Gastroenterol 1989; 84:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/51\">",
"      Anda RF, Williamson DF, Escobedo LG, Remington PL. Smoking and the risk of peptic ulcer disease among women in the United States. Arch Intern Med 1990; 150:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/52\">",
"      Chan FK, Sung JJ, Lee YT, et al. Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori? Am J Gastroenterol 1997; 92:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/53\">",
"      Bardhan KD, Graham DY, Hunt RH, O'Morain CA. Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. Helicobacter 1997; 2:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/54\">",
"      Boyd EJ, Wilson JA, Wormsley KG. The fate of asymptomatic recurrences of duodenal ulcer. Scand J Gastroenterol 1984; 19:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16345/abstract/55\">",
"      Wolosin JD, Gertler SL, Peterson WL, et al. Gastric ulcer recurrence: follow-up of a double-blind, placebo-controlled trial. J Clin Gastroenterol 1989; 11:12.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 27 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16345=[""].join("\n");
var outline_f15_61_16345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REFRACTORY ULCERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Refractory symptoms versus ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Conditions underlying refractory ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Persistent H. pylori infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Large ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Impaired healing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Acid hypersecretory states",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Impaired response to antisecretory agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Comorbid diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8366970\">",
"      - Emotional stress",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19608022\">",
"      - Unusual causes of refractory ulceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Antisecretory therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RECURRENT ULCERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Factors influencing recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Breakthrough recurrences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/27\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/27|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/23/5501\" title=\"table 1\">",
"      Causes of refractory or recurrent peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=related_link\">",
"      Approach to refractory gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24919?source=related_link\">",
"      Diagnosis of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12455?source=related_link\">",
"      Management of duodenal ulcers in patients infected with Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=related_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=related_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=related_link\">",
"      Patient information: Peptic ulcers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3658?source=related_link\">",
"      Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=related_link\">",
"      Pharmacology of antiulcer medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33688?source=related_link\">",
"      Role of surgery in the management of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=related_link\">",
"      Unusual causes of peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_61_16346="Seafood allergies: Fish and shellfish";
var content_f15_61_16346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Seafood allergies: Fish and shellfish",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/61/16346/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/61/16346/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/61/16346/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/61/16346/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/61/16346/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/61/16346/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/61/16346/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seafood allergy is the most common food allergy in adults and among the six most prevalent food allergies in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term \"seafood\" encompasses the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vertebrate finned fish, such as salmon, tuna, and cod",
"     </li>",
"     <li>",
"      Crustaceans, such as shrimp, prawn, crab, lobster, and crawfish",
"     </li>",
"     <li>",
"      Mollusks, such as squid, snails, and bivalves (scallops, clams, oysters, mussels, and others)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term \"shellfish\", a subset of seafood, includes crustaceans and mollusks.",
"   </p>",
"   <p>",
"    Seafood allergies are immunologic responses to proteins in these foods, and include IgE antibody-mediated allergy as well as other allergic syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. They are distinct from adverse reactions due to toxins or infectious contaminants, which are not immune-based. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19096?source=see_link\">",
"     \"Marine toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this topic review, the epidemiology, pathogenesis, clinical features, diagnosis, and management of seafood allergies will be presented. Issues of cross-reactivity among different forms of seafood are also addressed. General discussions of food allergy are presented separately in appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General population",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergies to seafood are estimated to affect 1 to 2 percent of the adult population and less than 1 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Allergy to shellfish is among the leading causes of food allergy in adults, and the most common cause of food-allergic emergency department visits [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several large studies have provided estimates of prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6-8,11\">",
"     6-8,11",
"    </a>",
"    ]. One multinational survey of 17,280 adults (aged 20 to 44 years) from 15 countries questioned participants about foods that \"nearly always\" caused \"illness\" or \"trouble\" [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/7\">",
"     7",
"    </a>",
"    ]. Shrimp, oyster, and fish were implicated by 2.3, 2.3, and 2.2 percent, respectively. In a random calling telephone survey in Canada, probable shellfish allergy was reported for 0.5 percent of children and 1.7 percent of adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/8\">",
"     8",
"    </a>",
"    ]. The same study found rates of fish allergy to be 0.2 percent of children and 0.6 percent of adults.",
"   </p>",
"   <p>",
"    Internationally, patterns of seafood consumption likely influence the prevalence of specific fish and shellfish allergies. As examples, allergy to whelk is seen in Korea, where this mollusk is a popular form of seafood, and barnacle allergy has been reported in the Portuguese population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A random calling survey in Singapore found a reported rate of shellfish allergy of 7.2 percent in 4 to 6 year olds and 11.6 percent in 14 to 16 year olds; applying features of a convincing history reduced these rates to 1.2 percent and 5.2 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/14\">",
"     14",
"    </a>",
"    ]. However, these rates are higher than similar studies from the US and Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An American study estimated the prevalence of seafood allergy using a nationwide, cross-sectional, telephone survey, in which a standardized questionnaire was administered to households chosen by randomly-generated phone numbers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6\">",
"     6",
"    </a>",
"    ]. Criteria were established in advance to define seafood allergy by either a convincing history of symptoms (eg, urticaria, angioedema, trouble breathing, oral pruritus, or throat closing) or a diagnosis of allergy by a clinician. This study did not attempt to determine a rate of isolated gastrointestinal reactions to seafood. A total of 5529 households completed the survey (67.3 percent participation rate), representing a census of 14,948 individuals. Fish or shellfish allergy defined by established criteria was reported in 6 percent of households and among individuals as follows: 2.3 percent for any seafood allergy, 2 percent for shellfish, 0.4 percent for fish, and 0.2 percent for both fish and shellfish.",
"   </p>",
"   <p>",
"    This study also revealed the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevalence rates in children were significantly lower than those in adults in all categories, as follows: any seafood allergy (0.6 versus 2.8 percent), shellfish (0.5 versus 2.5 percent), and fish (0.2 versus 0.5 percent). Boys were affected more often than girls.",
"     </li>",
"     <li>",
"      In adults, the gender trend was reversed and rates in females were significantly higher than in males for both shellfish allergy (2.6 versus 1.5 percent) and fish allergy (0.6 versus 0.2 percent).",
"     </li>",
"     <li>",
"      The highest rates of seafood allergy were reported by African Americans, with shellfish reported as the leading cause.",
"     </li>",
"     <li>",
"      The most common reported fish allergies, in order of decreasing frequency, were: salmon, tuna, catfish, cod, flounder, halibut, trout, and bass.",
"     </li>",
"     <li>",
"      The most common reported shellfish allergies, in decreasing frequency, were: shrimp, crab, lobster, clam, oyster, and mussel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Referral populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seafood allergy accounts for up to one-third of serious allergic reactions to food in patients referred for allergy evaluations. Studies are relatively consistent around the world [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/15-20\">",
"     15-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major allergenic proteins in seafood that are responsible for IgE-mediated reactions have been identified. Persons with seafood allergy may react to these",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other seafood proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parvalbumins are important allergens in fish [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tropomyosins are major allergens in shellfish and are also present in other arthropods (ie, dust mites, cockroaches), accounting for cross-reactivity between these groups [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Cross-reactivity with non-food allergens'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In shrimp, the muscle proteins myosin light chain and sarcoplasmic calcium-binding protein are other prominent allergens [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis of non-IgE mediated seafood allergy is unclear. A syndrome that clinically resembles protein-induced enterocolitis has been described in both children and adults. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Non IgE-mediated reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated allergic reactions are the most commonly described type of allergic reactions to seafood ingestion. These may present as generalized reactions, asthmatic reactions in response to occupational or household exposures, or as food-dependent, exercise-induced anaphylaxis.",
"   </p>",
"   <p>",
"    IgE-mediated reactions are rapid in onset (usually within minutes to an hour after ingestion) and extra-gastrointestinal manifestations, such as urticaria, angioedema, respiratory symptoms, and laryngeal edema, are common (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"     table 1",
"    </a>",
"    ). These can range in severity from mild to life threatening anaphylaxis; severe reactions are not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/2,28-30\">",
"     2,28-30",
"    </a>",
"    ]. The clinical features of IgE-mediated reactions are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occupational and household exposures involving inhalation of cooking or processing vapors may cause asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/4,31,32\">",
"     4,31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38903?source=see_link\">",
"     \"Occupational asthma: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Food-dependent, exercise-induced anaphylaxis to seafood has also been reported. In this condition, the food causes symptoms only if ingestion is followed soon after by exercise or exertion, but is tolerated in the absence of exertion. Wheat products and seafood are the two most frequently implicated foods in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated fish and shellfish allergies can vary from mild to severe. In the US prevalence study, 60 to 70 percent of respondents experienced",
"    <span class=\"nowrap\">",
"     urticaria/angioedema,",
"    </span>",
"    and over one-half reported dyspnea or throat tightness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6\">",
"     6",
"    </a>",
"    ]. Consistent with this, approximately one-half of reactions prompted evaluation by a clinician or care in an emergency room. Despite the severe symptoms, administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    was provided to only 16 percent of individuals treated in medical settings.",
"   </p>",
"   <p>",
"    Several deaths from seafood allergy have been recorded. In a registry of food-induced fatal anaphylaxis comprised primarily of children, 1 of 32 deaths was due to fish, and in a report of seven deaths, one was reported to crab and one to fish [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In a United Kingdom registry of fatalities from anaphylaxis, 3 of 33 fatalities to a known food were caused by seafood [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Non IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several other reactions to seafood exposure that are not IgE-mediated. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Food protein-induced enterocolitis in children, a non-IgE mediated allergic reaction",
"     </li>",
"     <li>",
"      An enterocolitis-like reaction in adults",
"     </li>",
"     <li>",
"      Contact dermatitis in those with occupational and household skin exposure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Gastrointestinal reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food protein-induced enterocolitis has been described in children in response to fish, although there is a paucity of data on this entity. In the largest series of 14 children diagnosed between the ages of 9 and 12 months of age, symptoms consisted of vomiting, diarrhea, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/35\">",
"     35",
"    </a>",
"    ]. Three presented with a sepsis-like picture. Reactions occurred from a few minutes to up to six hours after ingestion. Skin prick tests were negative in all patients, and fish-specific serum IgE was positive in just one patient. Nine had the reactions confirmed by oral challenge. Four of these children eventually became tolerant of the causal food. Protein-induced enterocolitis in children is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seafood may also cause an enterocolitis-like disorder in adults, with delayed onset of nausea, crampy abdominal pain, and protracted vomiting or diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/1\">",
"     1",
"    </a>",
"    ]. One severe case involved hypotension and blood-tinged diarrhea, reproduced upon oral challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/36\">",
"     36",
"    </a>",
"    ]. This appears to be primarily reported in response to mollusks. Adults typically present after having experienced this on several occasions, reporting that they had attributed the first one or two reactions to possible food poisoning. Indeed, these reactions clinically mimic diarrhetic shellfish poisoning (DSP), beginning one to six hours after ingestion and resolving within a few hours to three days, depending on severity. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The etiology of these enterocolitis-like reactions in adults is unclear. Their repeated occurrence in certain individuals suggests either that some persons are more susceptible to toxic components in these foods, or that this reaction represents a form of allergy. There are very few studies of the pathogenesis of these reactions, although one study of adults with isolated gastrointestinal symptoms to various types of seafood included six patients who reacted repeatedly to oyster, in whom specific IgE was generally undetectable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/37\">",
"     37",
"    </a>",
"    ]. No formal information about epidemiology, range of severity, or prognosis is available, and there are no data to guide informed recommendations about this type of reaction. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Delayed gastrointestinal reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Allergic contact dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic contact dermatitis can result from occupational skin exposure to seafood, in food handlers, for example [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/4,32\">",
"     4,32",
"    </a>",
"    ]. Disruption of the skin barrier has been implicated as a risk factor for the development of this condition in exposed workers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Age of onset and natural course",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the American prevalence survey reviewed previously, allergy developed in adulthood for 40 and 60 percent of individuals with fish and shellfish allergy, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6\">",
"     6",
"    </a>",
"    ]. Fifty-eight percent reported multiple reactions, with two to five episodes being typical [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6\">",
"     6",
"    </a>",
"    ]. Fifteen to 20 percent of people experienced more than six reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seafood allergy is considered to be persistent in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/35,38,39\">",
"     35,38,39",
"    </a>",
"    ]. In a study evaluating IgE binding to various epitopes of major shrimp allergens, children showed stronger and more diverse IgE binding than adults, implying the allergy may wane with time. [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/40\">",
"     40",
"    </a>",
"    ]. In the American telephone-based survey, only 3 to 4 percent of individuals with seafood allergy reported developing tolerance over time [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6\">",
"     6",
"    </a>",
"    ]. However, loss of fish allergy during childhood or in adulthood has been reported, although the extent to which this occurs is not well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/39,41\">",
"     39,41",
"    </a>",
"    ]. Recurrence of fish allergy after tolerance has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general discussion of the diagnosis of food allergy is presented elsewhere. A summary of this information, with a focus on those aspects that are most relevant to the diagnosis of seafood allergy, is provided below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the exception of in vitro immunoassays for specific IgE (which are commonly referred to as IgE RAST tests), other diagnostic allergy procedures, including skin testing and food challenges, should be performed by allergy specialists with training in the management of serious allergic reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;For suspected IgE-mediated reactions, the history of an immediate reaction consisting of typical allergic symptoms, supported by positive tests for specific IgE antibodies, is sufficient to establish a diagnosis. Either skin prick tests or in vitro tests for IgE are usually performed initially. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The positive predictive value of skin prick testing with commercial seafood extracts and IgE immunoassays has not been compared to clinical reactivity in appropriate populations using oral food challenges. This is true for seafood and for most foods.",
"   </p>",
"   <p>",
"    However, the negative predictive value of skin prick testing with commercial food extracts is generally high. In our clinic, we have found that negative skin tests with commercial seafood extracts that are in accordance with the clinical history are usually reliable. If there is uncertainty or the clinician has limited experience with a specific commercial extract, the actual food can be used for skin testing instead.",
"   </p>",
"   <p>",
"    If the history is suggestive of allergy, and one or both forms of testing are negative, then it is useful to repeat skin testing using the implicated seafood, prepared in a manner similar to the exposure that caused the reaction (eg, raw if sushi caused the reaction). (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Diagnostic pitfalls'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In each case of diagnosed seafood allergy, possible allergy to cross-reactive fish or shellfish must be addressed. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Cross-reactivity'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H31\">",
"     'Eating other seafood'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If the history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IgE test results do not clearly indicate an allergy, then clinician-supervised oral food challenges would be required to exclude the diagnosis. The use of challenges in the diagnosis of food allergy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of suspected occupational asthma due to seafood allergy, which is also IgE-mediated, involves skin prick testing, pulmonary function testing, and possible bronchoprovocation challenge. Occupational asthma is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link\">",
"     \"Occupational asthma: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE tests are expected to be negative if the symptoms do not suggest an IgE-mediated reaction, such as delayed gastrointestinal reactions or contact dermatitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis is confirmed by challenge in the case of food protein-induced enterocolitis in children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"       \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of enterocolitis in adults would also require challenge, although patients who have experienced these reactions on several occasions may decline, understandably. Diagnosis based upon history alone is reasonable in cases of recurrent reactions, as this essentially rules out incidental poisoning or bacterial contamination.",
"     </li>",
"     <li>",
"      In cases of contact dermatitis, patch testing with a preparation of the seafood in question may be informative, although such testing is not standardized. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link\">",
"       \"Overview of dermatitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnostic pitfalls",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several additional factors that can make the diagnosis of seafood allergy challenging (",
"    <a class=\"graphic graphic_table graphicRef65968 \" href=\"UTD.htm?27/20/27979\">",
"     table 2",
"    </a>",
"    ). Digestion, various processing methods",
"    <span class=\"nowrap\">",
"     (heating/canning),",
"    </span>",
"    and preparation issues (eg, which part of the fish is eaten) may influence the amount of relevant allergen in the final meal, as demonstrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies suggest that fish preparation methods (eg, boiling versus frying versus eating raw) may impact the allergenicity of fish in different ways [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/43\">",
"       43",
"      </a>",
"      ]. Also, the impact of these factors can also vary among species of fish.",
"     </li>",
"     <li>",
"      During oral food challenges in children, it was observed that children passed food challenges to lyophilized fish in capsules but reacted to fresh fish [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Digestion can also reduce the potential allergenicity of fish allergen, and may result in variable clinical outcomes depending upon, for example, stomach acidity [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/45-47\">",
"       45-47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The part of the fish ingested can have different levels of the major allergen, such that dark or red muscle may lack the allergen compared to white muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. It is also possible to be allergic to caviar (fish roe) but not fish [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of these variables, it is important to repeat skin testing using the same seafood, prepared in a similar manner to that which caused the reaction, whenever a convincing clinical history cannot be readily validated by routine testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Allergy to canned tunafish",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who react to fresh tuna and salmon will typically tolerate canned versions of these fish, presumably because of modification of allergens during processing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/44,51\">",
"     44,51",
"    </a>",
"    ]. Because of this, commercial extracts and possibly fresh foods may be required for skin testing patients who reacted to fresh forms of these fish. If an individual has reacted to fresh tuna or salmon and is interested in eating the canned form, additional testing and supervised oral food challenges are suggested.",
"   </p>",
"   <p>",
"    Conversely, allergy specifically to canned tuna has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/52\">",
"     52",
"    </a>",
"    ]. In addition, some brands of canned tuna contain soy or milk proteins that are added during processing, and this possibility should also be considered in patients who react only to canned tuna (and may apply to other canned fish).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Anisakis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergy to the fish parasite Anisakis simplex represents another potential diagnostic dilemma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. Anisakis simplex is a nematode that infects fish worldwide and can cause several health issues in humans. Humans are accidental hosts who can become transiently infected as a result of eating the raw or undercooked flesh of infected fish (typically herring, hake, black plaice and cod) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Deep freezing and rethawing of fish kills the parasite [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/59\">",
"     59",
"    </a>",
"    ]. Some countries (including the United States) have legislation requiring that any fish intended for consumption raw must be deep frozen for specified time periods (which differ depending on the temperatures used) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/59\">",
"     59",
"    </a>",
"    ]. However, this may not be strictly enforced [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/60\">",
"     60",
"    </a>",
"    ]. The majority of recent cases of Anisakis reactions have been reported by Spanish investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One manifestation of Anisakis allergy is a generalized reaction involving urticaria, angioedema, abdominal pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anaphylaxis, which develops as the live larvae penetrate the gastric mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Gastrointestinal symptoms may be minimal or absent and a delay in the onset of symptoms of between 2 and 24 hours is typical [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. This delay between consumption of raw fish and onset of symptoms can be an important diagnostic clue to the presence of Anisakis allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major allergenic protein (Ani s 7) in Anisakis species has been identified, although a test for the presence of specific IgE to Ani s 7 is not yet commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/65\">",
"     65",
"    </a>",
"    ]. It appears that parasite larvae must be viable to induce the reaction described previously, as neither skin testing with whole body extracts nor oral challenge with lyophilized parasites reproduces symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/54,55,66\">",
"     54,55,66",
"    </a>",
"    ]. Excretory or secretory proteins produced by the live larvae have been implicated as possible allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/55,63\">",
"     55,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anisakis allergy likely contributes to occupational respiratory allergy and contact dermatitis in fish processing workers. In one study, sensitization to Anisakis was as common as that to fish [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/66\">",
"     66",
"    </a>",
"    ]. However, it is currently not clear what other clinical syndromes can be correctly attributed to Anisakis allergy. The optimal approach to skin testing is also uncertain, although prick-by-prick skin testing with live larvae appears to be most consistently positive in patients with",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    or anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/63\">",
"     63",
"    </a>",
"    ]. In contrast, the diagnosis of acute infection with Anisakis can be confirmed with serologic and gastroenterological tests and is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44168?source=see_link\">",
"     \"Miscellaneous nematodes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Scombroid poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary masquerader of IgE-mediated reactions is scombroid fish poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. In 1999, 19 cases of scombroid poisoning were reported in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/5\">",
"     5",
"    </a>",
"    ], although many more cases likely go undetected. The epidemiology, clinical manifestations, and treatment of scombroid poisoning are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19096?source=see_link&amp;anchor=H9#H9\">",
"     \"Marine toxins\", section on 'Scombroid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several types of dark-meat fish (eg, tuna, bluefish, mackerel, and others) elaborate histamine-like chemicals during spoilage that are produced by bacteria in the fish flesh. Upon ingestion, these chemicals can cause reactions that mimic IgE-mediated allergy, with flushing and urticaria beginning within an hour of eating [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/5\">",
"     5",
"    </a>",
"    ]. Symptoms that help distinguish these reactions from allergy include perioral sensations of tingling and burning, headache, and dizziness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with scombroid poisoning do not have evidence of specific IgE to that type of fish. The absence of specific IgE may be demonstrated by skin prick testing with a different sample of the same type of fish, a commercial extract of that fish, or in vitro assays. Challenge with the seafood in question may be needed for conclusive diagnosis of scombroid poisoning.",
"   </p>",
"   <p>",
"    Other approaches to diagnosis are possible if the patient saved or can obtain some of the fish that caused the reaction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A sample of the culprit fish can be analyzed for histamine content, as discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19096?source=see_link&amp;anchor=H9#H9\">",
"       \"Marine toxins\", section on 'Scombroid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A sample of the fish can be pulverized, and used in prick-by-prick skin testing and compared to the result with a commercial extract of the same fish. If only the culprit fish sample is positive, then it can be used to test a nonallergic volunteer [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/69\">",
"       69",
"      </a>",
"      ]. If both individuals react positively to the culprit fish, then it can be deduced that histamine-like chemicals in the fish sample are the cause of these nonspecific positive reactions, and the diagnosis is scombroid poisoning.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other types of seafood poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other types of seafood poisoning (eg, toxins such as Ciguatoxin or contamination such as Botulism and others) may result in a variety of neurologic and gastrointestinal symptoms that usually do not resemble IgE-mediated allergic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/5\">",
"     5",
"    </a>",
"    ]. The various forms of seafood poisoning are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19096?source=see_link\">",
"     \"Marine toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diarrhetic shellfish poisoning (DSP) causes the delayed onset of nausea, vomiting, and colicky abdominal pain, and can mimic enterocolitis, as mentioned previously. DSP results from the ingestion of mollusks contaminated with okadaic acid produced by dinoflagellates. This disorder generally comes to medical attention because of outbreaks. However, because DSP can be relatively mild and self-limited, it is unclear what proportion of cases is unreported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CROSS-REACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, parvalbumins in fish and tropomyosins in shellfish are responsible for the majority of IgE-mediated allergies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. People with seafood allergy may react to these",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to other seafood proteins. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because the major allergenic proteins for fish and shellfish are different, individuals are usually allergic to one group or the other, although it is possible to be allergic to both. Allergy to both fish and shellfish was reported by approximately 10 percent of all those reporting any seafood allergy in the American telephone survey previously discussed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6\">",
"     6",
"    </a>",
"    ]. One important limitation of this study is possible underestimation of cross-reactivity, since people with an initial reaction who subsequently avoid all seafood may report that they react to only one type. Formal challenge studies with sufficient numbers of people would be required to establish definite estimates.",
"   </p>",
"   <p>",
"    Among persons with allergy to a fish or shellfish, approximately 30 to 50 percent will react clinically to more than one type of fish or shellfish [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/30,70\">",
"     30,70",
"    </a>",
"    ]. Conversely, it is also possible to be allergic to just one specific type of fish or shellfish, such as tropical sole, swordfish, or one type of shrimp [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. Patients in the latter group generally lack IgE antibodies to the major allergenic proteins and are presumed to be sensitized to a species-specific protein.",
"   </p>",
"   <p>",
"    As is the case for many foods that share homologous proteins, sensitization (ie, positive allergy tests) to multiple species is more common than clinical reactivity (ie, the development of actual symptoms on ingestion). A Spanish study evaluated the relevance of sensitization to six regionally important species in 79 children with fish allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/74\">",
"     74",
"    </a>",
"    ]. While all subjects had positive skin tests to multiple species, only 39 percent had clinical reactions. Thus, positive test results alone are not sufficient to determine which related foods will cause symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Fish",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated that fish-allergic subjects often react to more than one type of fish, although this is not universal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/30,75-77\">",
"     30,75-77",
"    </a>",
"    ]. The following are representative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the American telephone survey presented previously, reported reactions to multiple fish among those with any fish allergy was 67 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6\">",
"       6",
"      </a>",
"      ]. Among the 58 individuals with fish allergy, 19 reported a reaction to only one type, 5 to two types, 13 to three to nine types, and the remainder was uncertain.",
"     </li>",
"     <li>",
"      Ten fish-allergic American children were evaluated with double-blind, placebo-controlled oral food challenges (DBPCFCs) to between four and six different species of fish [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/2\">",
"       2",
"      </a>",
"      ]. All reacted to at least one type, and three children reacted to more than one type.",
"     </li>",
"     <li>",
"      In a study of 20 codfish-allergic Italian children, positive skin tests to other fish were documented in 5 to 100 percent for each of nine species tested [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/78\">",
"       78",
"      </a>",
"      ]. For those who ingested the fish to which antibody was detected, the clinical reaction rate per fish based upon history ranged from 25 to 100 percent. In these cod-allergic children, eel, bass, sole and tuna most frequently provoked reactions while salmon, sardine, and dogfish were least likely to induce symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, a fish allergic patient is at high risk for reactions to other fish. There is insufficient data to predict which types of fish are more likely to be tolerated based upon the known allergy. In addition, skin testing or in vitro tests alone are often not sufficient to identify which types will cause clinical reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Shellfish",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is also common for patients allergic to shellfish to react clinically to more than one type of shellfish. Extensive cross-reactivity among shellfish is explained by the fact that invertebrate tropomyosin is a pan allergen with significant sequence homology throughout many invertebrate species, including crustaceans, mollusks, squid, octopus, parasites, and non-marine insects (such as cockroaches, grasshoppers, and dust mites) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/79-86\">",
"     79-86",
"    </a>",
"    ]. However, there are clearly other factors that influence cross-reactivity, as homology cannot be used to predict an individual patient's sensitivity patterns. Invertebrate tropomyosins demonstrate less homology with vertebrate tropomyosins [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the few studies examining cross-reactivity among foods within the crustacean or mollusk groups, sensitization was very high, and clinical reactivity was lower although very significant. The following studies provide information on these observations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6,82,88,89\">",
"     6,82,88,89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 16 atopic, shrimp-allergic patients, greater than 80 percent had positive prick skin tests to crab, crayfish, and lobster [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/88\">",
"       88",
"      </a>",
"      ]. Patients were not challenged to determine if they developed symptoms to the test-positive foods.",
"     </li>",
"     <li>",
"      In the American telephone survey, 232 people had allergy to shrimp, lobster,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      crab [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6\">",
"       6",
"      </a>",
"      ]. Of these, 62 percent indicated allergy to one, 20 percent to two, and 18 percent to all three types. Thus, based on patient-provided history, nearly 40 percent of patients reacted to more than one type of crustacean.",
"     </li>",
"     <li>",
"      In a study evaluating nine patients with shrimp anaphylaxis, sera from all patients reacted specifically with the tropomyosins of 13 crustaceans and mollusks [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/82\">",
"       82",
"      </a>",
"      ]. However, patients were not challenged, so the clinical correlation is unclear.",
"     </li>",
"     <li>",
"      In the American telephone survey, 67 people reacted to scallops, clams, oysters, or mussels [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/6\">",
"       6",
"      </a>",
"      ]. Of these, 51 percent reacted to just one type of mollusk, 19 percent to two, 8 percent to three, and 22 percent to all four types. In addition, 14 percent (41 persons) of those with shellfish allergy reported an allergy to both crustaceans and mollusks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, based upon limited data, up to 80 percent of patients with an allergy to one crustacean may be sensitized to other crustaceans, and approximately 40 percent may react clinically upon ingestion. Among mollusk-allergic patients, approximately 50 percent report reactions to more than one type of mollusk. Between 10 to 15 percent of patients allergic to any shellfish are allergic to both crustaceans and mollusks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cross-reactivity with non-food allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invertebrate tropomyosin is also found in several non-marine allergenic organisms, such as dust mites and cockroaches. In a report of asthma induced by snail consumption in 28 patients, RAST inhibition studies indicated that house dust mite sensitization was the likely initial event, suggesting that sensitization by the respiratory route may predispose to the development of subsequent allergy upon seafood ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have implicated cross-reactivity between tropomyosins as responsible for the development of shellfish allergy in patients receiving immunotherapy for dust mite [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. However, this phenomenon has not been adequately documented and other studies do not support the hypothesis. Myosin light chain in shrimp is homologous to an important allergen in cockroach, although the clinical significance of this is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no cross-reactivity between seafood allergens and radiocontrast media. This misconception is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=see_link&amp;anchor=H9#H9\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of seafood allergy does not differ from that of other food allergies and requires instructions on avoidance and education about treatment of reactions in the event of accidental exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Dietary recommendations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients must avoid the specific food that induced symptoms. In addition, general avoidance of all fish or all shellfish may be the safest and most practical strategy for people with severe reactions or reactions to multiple types of seafood.",
"   </p>",
"   <p>",
"    Counseling about avoidance should include discussions about the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cross-contact",
"      </strong>",
"      &mdash; Patients must be counseled about accidental exposure to food allergens via cross-contact (ie, inadvertent exposure to the allergenic food by contamination of \"safe\" foods with small amounts of the culprit food). With seafood, this typically occurs at seafood counters, restaurants, and as a result of shared equipment (especially fryers). Reactions due to contact with contaminated saliva through kissing or sharing of utensils have also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Food labels",
"      </strong>",
"      &mdash; Patients must read all food labels. Legislation has been enacted in the United States mandating that the ingredients labels on food packages plainly identify the presence of eight specified allergenic foods. These eight foods include fish and crustacean shellfish (as well as milk, eggs, tree nuts, peanuts, wheat, and soybeans) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/94\">",
"       94",
"      </a>",
"      ]. Mollusks are not included. This legislation applies to all foods packaged since January 2006, although foods labeled before January 2006 are still available in stores.",
"     </li>",
"     <li>",
"      <strong>",
"       Unexpected and non-food sources",
"      </strong>",
"      &mdash; Seafood components can appear in unexpected foods, as well as in non-food items. As an example, fish gelatin is a food additive derived from fish skin. The use of fish gelatin as a food additive is increasing in parallel with concerns over the risk of bovine spongiform encephalopathy with bovine gelatin [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/95\">",
"       95",
"      </a>",
"      ]. Usual doses of fish gelatin are tolerated by most fish allergic persons, but anaphylactic reactions have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/95-97\">",
"       95-97",
"      </a>",
"      ]. Results from one small series suggest that some individuals with fish allergy may tolerate fish oil supplements as well [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/98\">",
"       98",
"      </a>",
"      ]. Medications, various health foods, and cosmetics may have ingredients derived from seafood, and labeling of non-food items is not strictly regulated.",
"      <br/>",
"      <br/>",
"      Fish products can be used as clarifying (or fining) agents in the manufacture of some wines. However, available studies indicate that residual fining agents are unlikely to cause allergic reactions in fish allergic individuals. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of food allergy: Avoidance\", section on 'Alcoholic beverages'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Aerosolized seafood allergens",
"      </strong>",
"      &mdash; Many of the allergenic proteins in seafood are stable and could be vaporized or released in steam during cooking. Although airborne exposures to food allergens are unlikely to cause anaphylaxis, respiratory reactions may occur from being near cooking fish or in fish markets [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/99,100\">",
"       99,100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Caution with anti-ulcer treatments",
"      </strong>",
"      &mdash; Anti-ulcer drugs increase gastric pH and may impair digestion of food proteins. In a mouse model, anti-ulcer drugs were reported to predispose to allergic reactions to caviar caused by unstable allergens that would be normally destroyed by digestion [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/45\">",
"       45",
"      </a>",
"      ]. A human study included four codfish-allergic patients who underwent DBPCFC to codfish that was predigested at either pH 2 or pH 3 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/101\">",
"       101",
"      </a>",
"      ]. The codfish preparation digested at pH 3 produced symptoms in these patients at either a lower dose, or after a shorter time interval, compared to codfish digested at pH 2, suggesting that anti-ulcer therapy may place patients at increased risk for reactions to ingested seafood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Eating other seafood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seafood is obviously not an essential component of the diet, and the most straightforward approach in managing any food allergy is",
"    <strong>",
"     complete",
"    </strong>",
"    avoidance of the culprit food and all similar foods. This strategy would be logically expected to minimize the chances of accidental exposure of the culprit food through cross-contact.",
"   </p>",
"   <p>",
"    However, there may be disadvantages to the strategy of avoiding all similar foods. There is some evidence, for example, that removing foods from the diet can increase the risk of becoming allergic to them. This appeared to be the case in a report of seven children with atopic conditions who were sensitized to fish but had no clinical symptoms on ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/102\">",
"     102",
"    </a>",
"    ]. The children were placed on fish-elimination diets and followed prospectively. Within the ensuing two to five years, all of the children developed clinical allergy to fish, including two with anaphylaxis. Similar examples of this phenomenon exist for other foods [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/103\">",
"     103",
"    </a>",
"    ]. Possible reasons for the heightened sensitivity include both lack of exposure and the opposite explanation, namely, ongoing low level exposure (through hidden sources or cross-contact).",
"   </p>",
"   <p>",
"    Thus, if a patient with allergy to a certain fish or shellfish wishes to continue eating other forms of seafood, the clinician's recommendations must carefully balance the patient's preferences with what is known about cross-reactivity among seafood. The severity of the patient's reaction also influences the decision. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Cross-reactivity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following scenarios illustrate some of the issues involved and our management approach. Individual clinicians may decide to adopt different strategies depending upon their level of expertise and the resources available (eg, ability to perform oral food challenges).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have experienced life-threatening anaphylaxis to a specific shellfish, we advise avoidance of all shellfish, largely because of the higher chance of encountering a cross-reactive tropomyosin in these foods. Similarly, a person who reacted to one finned fish would usually be advised to avoid all finned fish. We typically do NOT advise patients with serious reactions to shellfish to avoid finned fish (or vice versa), since the major allergens in shellfish and finned fish are different, as noted previously. However, patients must be wary of settings in which cross-contamination is common, such as seafood restaurants. It may be wise to avoid these settings altogether.",
"     </li>",
"     <li>",
"      For patients with non-life threatening reactions, we are more flexible in our approach. If patients are content to avoid all shellfish or finned fish (depending upon which group they reacted to), we do not discourage this approach. However, if a patient wishes to continue to include similar seafood in the diet, then a careful evaluation must be performed to determine which specific foods may be safely eaten. As an example, a patient who developed an allergy to codfish that is moderate in severity and has been avoiding all seafood for several months may ask about the safety of eating tuna, which had been a regular component of the patient's diet before the reaction.",
"      <br/>",
"      <br/>",
"      In this case, we would first perform skin testing with commercial extracts of tuna. If negative, we would allow the ingestion of tuna because the experience in our clinic suggests the negative predictive value of skin prick testing for seafoods is generally high.",
"      <br/>",
"      <br/>",
"      However, if there were any clinical suspicion of tuna allergy or if the clinician were uncomfortable proceeding without additional evaluation, skin testing and oral food challenge with fresh tuna should be performed. If skin tests were positive to tuna but the patient still had a strong interest in eating it, we would perform a cautious graded challenge to determine whether there was true clinical reactivity (because false-positive skin tests are not uncommon).",
"     </li>",
"     <li>",
"      We allow persons to continue to eat seafood that has not caused symptoms in the recent past, and which they have eaten regularly (similar to having just passed an oral food challenge). As an example, a patient with a newly diagnosed allergy to codfish who continued to eat tuna without incident after the reaction can simply continue to do so.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Management of reactions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of individuals with IgE-mediated seafood allergy is important because these reactions can be severe. As in other forms of food allergy, the severity of symptoms in a given individual may vary dramatically between reactions and the severity of an initial reaction should not be used to predict the patient's subsequent risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/104\">",
"     104",
"    </a>",
"    ]. Accordingly, all individuals diagnosed with IgE-mediated seafood allergy should have an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjector(s) available at all times [",
"    <a class=\"abstract\" href=\"UTD.htm?15/61/16346/abstract/105\">",
"     105",
"    </a>",
"    ]. Patients who have experienced anaphylaxis should have a written Anaphylaxis Action Plan. These measures are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Delayed gastrointestinal reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of children with food-protein induced enterocolitis caused by fish and other foods is presented in the specific topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data to guide recommendations about the treatment of delayed gastrointestinal reactions in adults, or the frequency with which patients require acute care. There are no reported fatalities from this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"       \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=see_link\">",
"       \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergy to fish or shellfish (crustaceans and mollusks) affects nearly 1 in 50 adults and is a leading cause of food-induced anaphylaxis. Fish is a common cause of food allergy in children, although rates of seafood allergy are lower than in adults. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Manifestations of IgE-mediated seafood allergy include",
"      <span class=\"nowrap\">",
"       urticaria/angioedema/anaphylaxis,",
"      </span>",
"      occupational asthma, and food-dependent, exercise-induced anaphylaxis. IgE-mediated seafood allergy can be severe and is usually long-lasting. There are also non-IgE mediated forms of allergy that present with delayed gastrointestinal reactions, although limited data are available about these reactions. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parvalbumins in fish and tropomyosins in shellfish are the proteins that are responsible for the majority of IgE-mediated allergies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Diagnosis and management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis of IgE-mediated seafood allergy is based upon a careful history supported by skin prick tests or in vitro tests for specific IgE. Positive tests for IgE may be present to seafood that is clinically tolerated, and a supervised oral food challenge may be necessary for definitive diagnosis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several factors may alter the allergenicity of seafood and complicate diagnosis, including preparation method, changes as a result of digestion, and the specific part of the fish that is consumed (",
"      <a class=\"graphic graphic_table graphicRef65968 \" href=\"UTD.htm?27/20/27979\">",
"       table 2",
"      </a>",
"      ). The differential diagnosis includes allergy to seafood parasites and nonallergic reactions to toxins in seafood. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnostic pitfalls'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rates of clinical cross-reactivity to different types of seafood within a group are high, ie, a person allergic to one fish is likely to react to others. In contrast, a minority (about 10 percent) of those allergic to any seafood are allergic to both fish and shellfish, although this observation is based on limited data. Because false positives on skin testing are possible, supervised challenge may be needed to definitely determine if a patient reacts to a specific seafood. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Cross-reactivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of seafood allergies includes instructions about avoidance of the specific culprit food, evaluations for reactivity to related foods in patients who wish to continue eating seafood, and education in the proper management of accidental exposures. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with life-threatening reactions are generally advised to avoid all related seafood. Some patients will choose to avoid all seafood, to minimize the risk of exposure through cross-contact. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among those with less severe reactions, some may wish to continue eating other forms of seafood in the future. In this case, testing and possibly oral challenges are needed to determine which specific foods are tolerated. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Eating other seafood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with IgE-mediated reactions to fish or shellfish should be equipped with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      autoinjectors, regardless of the severity of their initial reactions. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'IgE-mediated reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/1\">",
"      Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol 2010; 125:S116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/2\">",
"      Bernhisel-Broadbent J, Scanlon SM, Sampson HA. Fish hypersensitivity. I. In vitro and oral challenge results in fish-allergic patients. J Allergy Clin Immunol 1992; 89:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/3\">",
"      James JM, Helm RM, Burks AW, Lehrer SB. Comparison of pediatric and adult IgE antibody binding to fish proteins. Ann Allergy Asthma Immunol 1997; 79:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/4\">",
"      Jeebhay MF, Robins TG, Lehrer SB, Lopata AL. Occupational seafood allergy: a review. Occup Environ Med 2001; 58:553.",
"     </a>",
"    </li>",
"    <li>",
"     Chegini S, Metcalfe DD. Seafood toxins. In: Food allergy: Adverse reactions to foods and food additives, Metcalfe DD, Sampson HA, Simon RA (Eds), Blackwell Science, Malden, MA 2003. p.487.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/6\">",
"      Sicherer SH, Mu&ntilde;oz-Furlong A, Sampson HA. Prevalence of seafood allergy in the United States determined by a random telephone survey. J Allergy Clin Immunol 2004; 114:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/7\">",
"      Woods RK, Abramson M, Bailey M, Walters EH. International prevalences of reported food allergies and intolerances. Comparisons arising from the European Community Respiratory Health Survey (ECRHS) 1991-1994. Eur J Clin Nutr 2001; 55:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/8\">",
"      Ben-Shoshan M, Harrington DW, Soller L, et al. A population-based study on peanut, tree nut, fish, shellfish, and sesame allergy prevalence in Canada. J Allergy Clin Immunol 2010; 125:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/9\">",
"      Liu AH, Jaramillo R, Sicherer SH, et al. National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2010; 126:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/10\">",
"      Clark S, Bock SA, Gaeta TJ, et al. Multicenter study of emergency department visits for food allergies. J Allergy Clin Immunol 2004; 113:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/11\">",
"      Arshad SH, Tariq SM, Matthews S, Hakim E. Sensitization to common allergens and its association with allergic disorders at age 4 years: a whole population birth cohort study. Pediatrics 2001; 108:E33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/12\">",
"      Lee BJ, Park HS. Common whelk (Buccinum undatum) allergy: identification of IgE-binding components and effects of heating and digestive enzymes. J Korean Med Sci 2004; 19:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/13\">",
"      Marinho S, Morais-Almeida M, Gaspar A, et al. Barnacle allergy: allergen characterization and cross-reactivity with mites. J Investig Allergol Clin Immunol 2006; 16:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/14\">",
"      Shek LP, Cabrera-Morales EA, Soh SE, et al. A population-based questionnaire survey on the prevalence of peanut, tree nut, and shellfish allergy in 2 Asian populations. J Allergy Clin Immunol 2010; 126:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/15\">",
"      Crespo JF, Pascual C, Burks AW, et al. Frequency of food allergy in a pediatric population from Spain. Pediatr Allergy Immunol 1995; 6:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/16\">",
"      Novembre E, Cianferoni A, Bernardini R, et al. Anaphylaxis in children: clinical and allergologic features. Pediatrics 1998; 101:E8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/17\">",
"      Pumphrey RS, Stanworth SJ. The clinical spectrum of anaphylaxis in north-west England. Clin Exp Allergy 1996; 26:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/18\">",
"      Dibs SD, Baker MD. Anaphylaxis in children: a 5-year experience. Pediatrics 1997; 99:E7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/19\">",
"      Kemp SF, Lockey RF, Wolf BL, Lieberman P. Anaphylaxis. A review of 266 cases. Arch Intern Med 1995; 155:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/20\">",
"      Thong BY, Cheng YK, Leong KP, et al. Anaphylaxis in adults referred to a clinical immunology/allergy centre in Singapore. Singapore Med J 2005; 46:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/21\">",
"      Lopata AL, Lehrer SB. New insights into seafood allergy. Curr Opin Allergy Clin Immunol 2009; 9:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/22\">",
"      Swoboda I, Bugajska-Schretter A, Verdino P, et al. Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergy. J Immunol 2002; 168:4576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/23\">",
"      Ayuso R, Lehrer SB, Reese G. Identification of continuous, allergenic regions of the major shrimp allergen Pen a 1 (tropomyosin). Int Arch Allergy Immunol 2002; 127:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/24\">",
"      Gill BV, Rice TR, Cartier A, et al. Identification of crab proteins that elicit IgE reactivity in snow crab-processing workers. J Allergy Clin Immunol 2009; 124:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/25\">",
"      Sahabudin S, Misnan R, Yadzir ZH, et al. Identification of Major and Minor Allergens of Black Tiger Prawn (Penaeus monodon) and King Prawn (Penaeus latisulcatus). Malays J Med Sci 2011; 18:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/26\">",
"      Ayuso R, Grishina G, Bardina L, et al. Myosin light chain is a novel shrimp allergen, Lit v 3. J Allergy Clin Immunol 2008; 122:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/27\">",
"      Ayuso R, Grishina G, Ib&aacute;&ntilde;ez MD, et al. Sarcoplasmic calcium-binding protein is an EF-hand-type protein identified as a new shrimp allergen. J Allergy Clin Immunol 2009; 124:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/28\">",
"      Yunginger JW, Sweeney KG, Sturner WQ, et al. Fatal food-induced anaphylaxis. JAMA 1988; 260:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/29\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001; 107:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/30\">",
"      Helbling A, Haydel R Jr, McCants ML, et al. Fish allergy: is cross-reactivity among fish species relevant? Double-blind placebo-controlled food challenge studies of fish allergic adults. Ann Allergy Asthma Immunol 1999; 83:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/31\">",
"      Jeebhay MF, Cartier A. Seafood workers and respiratory disease: an update. Curr Opin Allergy Clin Immunol 2010; 10:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/32\">",
"      Howse D, Gautrin D, Neis B, et al. Gender and snow crab occupational asthma in Newfoundland and Labrador, Canada. Environ Res 2006; 101:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/33\">",
"      Beaudouin E, Renaudin JM, Morisset M, et al. Food-dependent exercise-induced anaphylaxis--update and current data. Eur Ann Allergy Clin Immunol 2006; 38:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/34\">",
"      Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/35\">",
"      Zapatero Rem&oacute;n L, Alonso Lebrero E, Mart&iacute;n Fern&aacute;ndez E, Mart&iacute;nez Molero MI. Food-protein-induced enterocolitis syndrome caused by fish. Allergol Immunopathol (Madr) 2005; 33:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/36\">",
"      Fernandes BN, Boyle RJ, Gore C, et al. Food protein-induced enterocolitis syndrome can occur in adults. J Allergy Clin Immunol 2012; 130:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/37\">",
"      Lehrer SB, McCants ML. Reactivity of IgE antibodies with crustacea and oyster allergens: evidence for common antigenic structures. J Allergy Clin Immunol 1987; 80:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/38\">",
"      Wood RA. The natural history of food allergy. Pediatrics 2003; 111:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/39\">",
"      Kajosaari M. Food allergy in Finnish children aged 1 to 6 years. Acta Paediatr Scand 1982; 71:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/40\">",
"      Ayuso R, S&aacute;nchez-Garcia S, Lin J, et al. Greater epitope recognition of shrimp allergens by children than by adults suggests that shrimp sensitization decreases with age. J Allergy Clin Immunol 2010; 125:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/41\">",
"      Solensky R. Resolution of fish allergy: a case report. Ann Allergy Asthma Immunol 2003; 91:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/42\">",
"      De Frutos C, Zapatero L, Martinez I, et al. Re-sensitization to fish in allergic children after a temporary tolerance period: two case reports. J Allergy Clin Immunol 2002; 109:S306 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/43\">",
"      Chatterjee U, Mondal G, Chakraborti P, et al. Changes in the allergenicity during different preparations of Pomfret, Hilsa, Bhetki and mackerel fish as illustrated by enzyme-linked immunosorbent assay and immunoblotting. Int Arch Allergy Immunol 2006; 141:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/44\">",
"      Bernhisel-Broadbent J, Strause D, Sampson HA. Fish hypersensitivity. II: Clinical relevance of altered fish allergenicity caused by various preparation methods. J Allergy Clin Immunol 1992; 90:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/45\">",
"      Untersmayr E, Sch&ouml;ll I, Swoboda I, et al. Antacid medication inhibits digestion of dietary proteins and causes food allergy: a fish allergy model in BALB/c mice. J Allergy Clin Immunol 2003; 112:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/46\">",
"      Untersmayr E, Poulsen LK, Platzer MH, et al. The effects of gastric digestion on codfish allergenicity. J Allergy Clin Immunol 2005; 115:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/47\">",
"      Untersmayr E, Bakos N, Sch&ouml;ll I, et al. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB J 2005; 19:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/48\">",
"      Lim DL, Neo KH, Goh DL, et al. Missing parvalbumin: implications in diagnostic testing for tuna allergy. J Allergy Clin Immunol 2005; 115:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/49\">",
"      Kobayashi A, Tanaka H, Hamada Y, et al. Comparison of allergenicity and allergens between fish white and dark muscles. Allergy 2006; 61:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/50\">",
"      M&auml;kinen-Kiljunen S, Kiistala R, Varjonen E. Severe reactions from roe without concomitant fish allergy. Ann Allergy Asthma Immunol 2003; 91:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/51\">",
"      Turner P, Ng I, Kemp A, Campbell D. Seafood allergy in children: a descriptive study. Ann Allergy Asthma Immunol 2011; 106:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/52\">",
"      Kelso JM, Bardina L, Beyer K. Allergy to canned tuna. J Allergy Clin Immunol 2003; 111:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/53\">",
"      Asturias JA, Eraso E, Moneo I, Mart&iacute;nez A. Is tropomyosin an allergen in Anisakis? Allergy 2000; 55:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/54\">",
"      Sastre J, Lluch-Bernal M, Quirce S, et al. A double-blind, placebo-controlled oral challenge study with lyophilized larvae and antigen of the fish parasite, Anisakis simplex. Allergy 2000; 55:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/55\">",
"      Baeza ML, Rodr&iacute;guez A, Matheu V, et al. Characterization of allergens secreted by Anisakis simplex parasite: clinical relevance in comparison with somatic allergens. Clin Exp Allergy 2004; 34:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/56\">",
"      Daschner A, Pascual CY. Anisakis simplex: sensitization and clinical allergy. Curr Opin Allergy Clin Immunol 2005; 5:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/57\">",
"      Petithory JC. [New data on anisakiasis]. Bull Acad Natl Med 2007; 191:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/58\">",
"      AAITO-IFIACI Anisakis Consortium. Anisakis hypersensitivity in Italy: prevalence and clinical features: a multicenter study. Allergy 2011; 66:1563.",
"     </a>",
"    </li>",
"    <li>",
"     Parasites. U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition. Fish and Fisheries Products Hazards and Controls Guidance, 3rd ed, 2001.",
"    </li>",
"    <li>",
"     Moskin J. Sushi Fresh From the Deep . . . the Deep Freeze. In: New York Times, April 8, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/61\">",
"      Daschner A, Alonso-G&oacute;mez A, Caba&ntilde;as R, et al. Gastroallergic anisakiasis: borderline between food allergy and parasitic disease-clinical and allergologic evaluation of 20 patients with confirmed acute parasitism by Anisakis simplex. J Allergy Clin Immunol 2000; 105:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/62\">",
"      Choi SJ, Lee JC, Kim MJ, et al. The clinical characteristics of Anisakis allergy in Korea. Korean J Intern Med 2009; 24:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/63\">",
"      Ventura MT, Tummolo RA, Di Leo E, et al. Immediate and cell-mediated reactions in parasitic infections by Anisakis simplex. J Investig Allergol Clin Immunol 2008; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/64\">",
"      Alonso-G&oacute;mez A, Moreno-Ancillo A, L&oacute;pez-Serrano MC, et al. Anisakis simplex only provokes allergic symptoms when the worm parasitises the gastrointestinal tract. Parasitol Res 2004; 93:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/65\">",
"      Rodr&iacute;guez E, Anad&oacute;n AM, Garc&iacute;a-Bodas E, et al. Novel sequences and epitopes of diagnostic value derived from the Anisakis simplex Ani s 7 major allergen. Allergy 2008; 63:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/66\">",
"      Nieuwenhuizen N, Lopata AL, Jeebhay MF, et al. Exposure to the fish parasite Anisakis causes allergic airway hyperreactivity and dermatitis. J Allergy Clin Immunol 2006; 117:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/67\">",
"      Chegini S, Metcalfe DD. Contemporary issues in food allergy: seafood toxin-induced disease in the differential diagnosis of allergic reactions. Allergy Asthma Proc 2005; 26:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/68\">",
"      Attaran RR, Probst F. Histamine fish poisoning: a common but frequently misdiagnosed condition. Emerg Med J 2002; 19:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/69\">",
"      Kelso JM, Lin FL. Skin testing for scombroid poisoning. Ann Allergy Asthma Immunol 2009; 103:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/70\">",
"      Sicherer SH. Clinical implications of cross-reactive food allergens. J Allergy Clin Immunol 2001; 108:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/71\">",
"      Asero R, Mistrello G, Roncarolo D, et al. True monosensitivity to a tropical sole. Allergy 1999; 54:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/72\">",
"      Kelso JM, Jones RT, Yunginger JW. Monospecific allergy to swordfish. Ann Allergy Asthma Immunol 1996; 77:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/73\">",
"      Morgan JE, O'Neil CE, Daul CB, Lehrer SB. Species-specific shrimp allergens: RAST and RAST-inhibition studies. J Allergy Clin Immunol 1989; 83:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/74\">",
"      Pascual C, Mart&iacute;n Esteban M, Crespo JF. Fish allergy: evaluation of the importance of cross-reactivity. J Pediatr 1992; 121:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/75\">",
"      Van Do T, Elsayed S, Florvaag E, et al. Allergy to fish parvalbumins: studies on the cross-reactivity of allergens from 9 commonly consumed fish. J Allergy Clin Immunol 2005; 116:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/76\">",
"      Aas K. Studies of hypersensitivity to fish. A clinical study. Int Arch Allergy Appl Immunol 1966; 29:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/77\">",
"      Hansen TK, Bindslev-Jensen C, Skov PS, Poulsen LK. Codfish allergy in adults: IgE cross-reactivity among fish species. Ann Allergy Asthma Immunol 1997; 78:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/78\">",
"      de Martino M, Novembre E, Galli L, et al. Allergy to different fish species in cod-allergic children: in vivo and in vitro studies. J Allergy Clin Immunol 1990; 86:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/79\">",
"      Daul CB, Slattery M, Reese G, Lehrer SB. Identification of the major brown shrimp (Penaeus aztecus) allergen as the muscle protein tropomyosin. Int Arch Allergy Immunol 1994; 105:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/80\">",
"      Leung PS, Chen YC, Gershwin ME, et al. Identification and molecular characterization of Charybdis feriatus tropomyosin, the major crab allergen. J Allergy Clin Immunol 1998; 102:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/81\">",
"      Leung PS, Chen YC, Mykles DL, et al. Molecular identification of the lobster muscle protein tropomyosin as a seafood allergen. Mol Mar Biol Biotechnol 1998; 7:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/82\">",
"      Leung PS, Chow WK, Duffey S, et al. IgE reactivity against a cross-reactive allergen in crustacea and mollusca: evidence for tropomyosin as the common allergen. J Allergy Clin Immunol 1996; 98:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/83\">",
"      Santos AB, Chapman MD, Aalberse RC, et al. Cockroach allergens and asthma in Brazil: identification of tropomyosin as a major allergen with potential cross-reactivity with mite and shrimp allergens. J Allergy Clin Immunol 1999; 104:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/84\">",
"      van Ree R, Antonicelli L, Akkerdaas JH, et al. Asthma after consumption of snails in house-dust-mite-allergic patients: a case of IgE cross-reactivity. Allergy 1996; 51:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/85\">",
"      Miyazawa H, Fukamachi H, Inagaki Y, et al. Identification of the first major allergen of a squid (Todarodes pacificus). J Allergy Clin Immunol 1996; 98:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/86\">",
"      Taylor SL. Molluscan shellfish allergy. Adv Food Nutr Res 2008; 54:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/87\">",
"      Ayuso R, Lehrer SB, Tanaka L, et al. IgE antibody response to vertebrate meat proteins including tropomyosin. Ann Allergy Asthma Immunol 1999; 83:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/88\">",
"      Daul CB, Morgan JE, Waring NP, et al. Immunologic evaluation of shrimp-allergic individuals. J Allergy Clin Immunol 1987; 80:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/89\">",
"      Waring NP, Daul CB, deShazo RD, et al. Hypersensitivity reactions to ingested crustacea: clinical evaluation and diagnostic studies in shrimp-sensitive individuals. J Allergy Clin Immunol 1985; 76:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/90\">",
"      Peroni DG, Piacentini GL, Bodini A, Boner AL. Snail anaphylaxis during house dust mite immunotherapy. Pediatr Allergy Immunol 2000; 11:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/91\">",
"      Asero R. Lack of de novo sensitization to tropomyosin in a group of mite-allergic patients treated by house dust mite-specific immunotherapy. Int Arch Allergy Immunol 2005; 137:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/92\">",
"      Fernandes J, Reshef A, Patton L, et al. Immunoglobulin E antibody reactivity to the major shrimp allergen, tropomyosin, in unexposed Orthodox Jews. Clin Exp Allergy 2003; 33:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/93\">",
"      Steensma DP. The kiss of death: a severe allergic reaction to a shellfish induced by a good-night kiss. Mayo Clin Proc 2003; 78:221.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food Allergen Labeling and Consumer Protection Act of 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/95\">",
"      Kuehn A, Hilger C, Hentges F. Anaphylaxis provoked by ingestion of marshmallows containing fish gelatin. J Allergy Clin Immunol 2009; 123:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/96\">",
"      Hansen TK, Poulsen LK, Stahl Skov P, et al. A randomized, double-blinded, placebo-controlled oral challenge study to evaluate the allergenicity of commercial, food-grade fish gelatin. Food Chem Toxicol 2004; 42:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/97\">",
"      Andr&eacute; F, Cavagna S, Andr&eacute; C. Gelatin prepared from tuna skin: a risk factor for fish allergy or sensitization? Int Arch Allergy Immunol 2003; 130:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/98\">",
"      Mark BJ, Beaty AD, Slavin RG. Are fish oil supplements safe in finned fish-allergic patients? Allergy Asthma Proc 2008; 29:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/99\">",
"      Roberts G, Golder N, Lack G. Bronchial challenges with aerosolized food in asthmatic, food-allergic children. Allergy 2002; 57:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/100\">",
"      Taylor AV, Swanson MC, Jones RT, et al. Detection and quantitation of raw fish aeroallergens from an open-air fish market. J Allergy Clin Immunol 2000; 105:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/101\">",
"      Untersmayr E, Vestergaard H, Malling HJ, et al. Incomplete digestion of codfish represents a risk factor for anaphylaxis in patients with allergy. J Allergy Clin Immunol 2007; 119:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/102\">",
"      Larramendi CH, Mart&iacute;n Esteban M, Pascual Marcos C, et al. Possible consequences of elimination diets in asymptomatic immediate hypersensitivity to fish. Allergy 1992; 47:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/103\">",
"      Fleischer DM, Conover-Walker MK, Christie L, et al. Peanut allergy: recurrence and its management. J Allergy Clin Immunol 2004; 114:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/104\">",
"      Sicherer SH, Furlong TJ, Mu&ntilde;oz-Furlong A, et al. A voluntary registry for peanut and tree nut allergy: characteristics of the first 5149 registrants. J Allergy Clin Immunol 2001; 108:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/61/16346/abstract/105\">",
"      Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol 2005; 115:S483.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2400 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16346=[""].join("\n");
var outline_f15_61_16346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Referral populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Non IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Gastrointestinal reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Age of onset and natural course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnostic pitfalls",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Allergy to canned tunafish",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Anisakis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Scombroid poisoning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other types of seafood poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CROSS-REACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Fish",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Shellfish",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cross-reactivity with non-food allergens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Dietary recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Avoidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Eating other seafood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Management of reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Delayed gastrointestinal reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Diagnosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2400\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2400|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21068\" title=\"table 1\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/20/27979\" title=\"table 2\">",
"      Pitfalls Dx seafood allergy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=related_link\">",
"      History and physical examination in the patient with possible food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19096?source=related_link\">",
"      Marine toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44168?source=related_link\">",
"      Miscellaneous nematodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=related_link\">",
"      Occupational asthma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38903?source=related_link\">",
"      Occupational asthma: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_61_16347="Strategies to control the rate of high order multiple gestations";
var content_f15_61_16347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Strategies to control the high order multiple pregnancy rate with IVF - 2004 data",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Strategy",
"      </td>",
"      <td class=\"subtitle1\">",
"       Country",
"      </td>",
"      <td class=\"subtitle1\">",
"       Rate of delivery per embryo transfer",
"      </td>",
"      <td class=\"subtitle1\">",
"       Rate of high order multiples per delivery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Laws to limit the number of embryos cultured",
"      </td>",
"      <td>",
"       Germany",
"      </td>",
"      <td>",
"       18.6",
"      </td>",
"      <td>",
"       1.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Laws to limit the number of embryos transferred",
"      </td>",
"      <td>",
"       United Kingdom",
"      </td>",
"      <td>",
"       25.8",
"      </td>",
"      <td>",
"       0.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Norway",
"      </td>",
"      <td>",
"       24.2",
"      </td>",
"      <td>",
"       0.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sweden",
"      </td>",
"      <td>",
"       24.9",
"      </td>",
"      <td>",
"       0.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Guidelines for number of embryos to transfer",
"      </td>",
"      <td>",
"       United States*",
"      </td>",
"      <td>",
"       34.0",
"      </td>",
"      <td>",
"       2.1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Data from: Anderson, AN, et al. Hum Reprod 2008; 23:756.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: CDC/SART Registry, 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16347=[""].join("\n");
var outline_f15_61_16347=null;
var title_f15_61_16348="Adjective Rating Scale";
var content_f15_61_16348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Adjective Rating Scale for pain assessment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 104px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Adjective Rating Scale allows patients to use descriptive terms to describe the severity of their pain. Scoring can be modified for conversion to a numeric scale.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987; 30:191. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16348=[""].join("\n");
var outline_f15_61_16348=null;
var title_f15_61_16349="Zoonoses causing encephalitis";
var content_f15_61_16349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important viral zoonoses that cause encephalitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Family/Virus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vector",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vertebrate host",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ecology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Geographic distribution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Epidemics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"6\" rowspan=\"1\">",
"        Togaviridae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eastern equine encephalitis",
"       </td>",
"       <td>",
"        Mosquitoes",
"       </td>",
"       <td>",
"        Birds",
"       </td>",
"       <td>",
"        R",
"       </td>",
"       <td>",
"        Americas",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Western equine encephalitis",
"       </td>",
"       <td>",
"        Mosquitoes",
"       </td>",
"       <td>",
"        Birds, rabbits",
"       </td>",
"       <td>",
"        R",
"       </td>",
"       <td>",
"        Americas",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Venezuelan equine encephalitis",
"       </td>",
"       <td>",
"        Mosquitoes",
"       </td>",
"       <td>",
"        Rodents",
"       </td>",
"       <td>",
"        R",
"       </td>",
"       <td>",
"        Americas",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"6\" rowspan=\"1\">",
"        Flaviviridae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dengue",
"       </td>",
"       <td>",
"        Mosquitoes",
"       </td>",
"       <td>",
"        Humans",
"       </td>",
"       <td>",
"        R, S, U",
"       </td>",
"       <td>",
"        Americas, Africa, Asia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Japanese encephalitis",
"       </td>",
"       <td>",
"        Mosquitoes",
"       </td>",
"       <td>",
"        Birds",
"       </td>",
"       <td>",
"        R, S",
"       </td>",
"       <td>",
"        Asia",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Murray Valley encephalitis",
"       </td>",
"       <td>",
"        Mosquitoes",
"       </td>",
"       <td>",
"        Birds",
"       </td>",
"       <td>",
"        R",
"       </td>",
"       <td>",
"        Australia",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        St. Louis encephalitis",
"       </td>",
"       <td>",
"        Mosquitoes",
"       </td>",
"       <td>",
"        Birds",
"       </td>",
"       <td>",
"        R, S, U",
"       </td>",
"       <td>",
"        Americas",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        West Nile encephalitis",
"       </td>",
"       <td>",
"        Mosquitoes",
"       </td>",
"       <td>",
"        Birds",
"       </td>",
"       <td>",
"        R, S, U",
"       </td>",
"       <td>",
"        Asia, Africa, North America,",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Powassan",
"       </td>",
"       <td>",
"        Ticks",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        R, S",
"       </td>",
"       <td>",
"        Europe, Northern United States, Canada",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tick-borne encephalitis",
"       </td>",
"       <td>",
"        Ticks",
"       </td>",
"       <td>",
"        Rodents",
"       </td>",
"       <td>",
"        R",
"       </td>",
"       <td>",
"        Europe, Asia",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"6\" rowspan=\"1\">",
"        Bunyaviridae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        La Crosse encephalitis",
"       </td>",
"       <td>",
"        Mosquitoes",
"       </td>",
"       <td>",
"        Rodents",
"       </td>",
"       <td>",
"        R, S",
"       </td>",
"       <td>",
"        North America",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        California encephalitis",
"       </td>",
"       <td>",
"        Mosquitoes",
"       </td>",
"       <td>",
"        Rodents",
"       </td>",
"       <td>",
"        R",
"       </td>",
"       <td>",
"        North America, Europe, Asia",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"6\" rowspan=\"1\">",
"        Reoviridae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colorado tick fever",
"       </td>",
"       <td>",
"        Ticks",
"       </td>",
"       <td>",
"        Rodents, small mammals",
"       </td>",
"       <td>",
"        R",
"       </td>",
"       <td>",
"        Western United States, Canada",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    R: rural; S: suburban; U: urban.",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16349=[""].join("\n");
var outline_f15_61_16349=null;
var title_f15_61_16350="Natural history diverticulitis";
var content_f15_61_16350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Natural history of diverticulitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 284px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16350=[""].join("\n");
var outline_f15_61_16350=null;
var title_f15_61_16351="Pericardial pleural effusion";
var content_f15_61_16351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Loculated pericardial effusion and contiguous pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 272px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical four-chamber view from a two dimensional echocardiogram shows a large pericardial effusion that is limited to the lateral wall of the left ventricle (LV). A pleural effusion is seen beginning at the pericardium and extending to the edge (and presumably beyond) of the sector.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_61_16351=[""].join("\n");
var outline_f15_61_16351=null;
